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( 57 ) ABSTRACT 
Antibody Fc polypeptides are provided that efficiently bind 
to both Fcy and Fca receptors . In certain aspects , a Fc 
polypeptide comprises a chimeric IgG CH2 domain having 
a al loop from IgA and an IgA CH3 domain . Recombinant 
antibodies comprising Fc polypeptides of the embodiments 
and methods for making and using such antibodies are 
likewise provided . 
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ANTIBODIES WITH ENGINEERED IGG FC In a further embodiment , a chimeric polypeptide is pro 
DOMAINS vided comprising ( a ) a chimeric CH2 domain comprising a 
mammalian IgG Fc CH2 domain having a al and / or a2 loop 
This application is a national phase application under 35 of a mammalian IgA Fc CH2 domain ; and ( b ) a mammalian 
U . S . C . $ 371 of International Application No . PCT / US2013 / 5 IgA Fc CH3 domain . In some aspects , the mammalian IgA 
057605 , filed Aug . 30 . 2013 , which claims the benefit of Fc CH3 domain is defined as a mammalian IgA Fc CH3 
U . S . Provisional Patent Application No . 61 / 717 , 568 , filed domain corresponding to amino acids 336 - 443 of a human 
Oct . 23 , 2012 , the entirety of each of which is incorporated IgA Fc , such as a human IgA1 ( SEQ ID NO : 9 ) or IgA2 CH3 
herein by reference . domain , based on the Kabat numbering scheme . IgA CH3 10 domains from several exemplary mammalian species are 
INCORPORATION OF SEQUENCE LISTING depicted in the alignment shown in FIG . 19 . In certain 
aspects , the al loop of a mammalian IgA is defined as a 
The sequence listing that is contained in the file named mammalian IgA al loop corresponding to amino acids 245 
" UTFB P1003WO ST25 . txt ” , which is 53 KB ( as mea - 257 of a human IgA Fc , according to the Kabat numbering 
sured in Microsoft Windows® ) and was created on Aug . 22 , 15 scheme ( e . g . , a human IgAl or IgA2 al loop ) . IgA al loop 
2013 , is filed herewith by electronic submission and is domains from several exemplary mammalian species are 
incorporated by reference herein . depicted in the alignment shown in FIG . 19 . Thus , in some 
aspects , the al loop of a mammalian IgA Fc CH2 domain 
BACKGROUND OF THE INVENTION comprises the sequence PALEDLLLGSEAN ( SEQ ID NO : 
20 14 ) or PALEDLLLGSEANG ( SEQ ID NO : 15 ) ( which 
1 . Field of the Invention includes an additional such that the length of the sequence 
The present invention relates generally to the field of corresponds with that of the IgG1 loop sequence ) . In yet a 
molecular biology and immunology . More particularly , it further aspect , a chimeric polypeptide is provided compris 
concerns molecular antibody design and antibody - based ing ( a ) a chimeric CH2 domain comprising a mammalian 
reagents and therapeutics . 25 IgG Fc CH2 domain having a al loop of a mammalian IgA 
2 . Description of Related Art Fc CH2 domain ; and one , two or three amino acid positions 
Antibody therapeutics have a dominant market share in from the a2 loop of a mammalian IgA Fc CH2 domain ; and 
the treatment of cancers and other human diseases with ( b ) a mammalian IgA Fc CH3 domain . Thus , in certain 
estimated sales exceeding USD $ 56 billion in 2011 . Anti - aspects , a chimeric polypeptide of the embodiments com 
bodies kill cancer cells in part by engaging and activating 30 prises an amino acid sequence at least 85 % , 90 % , 91 % 92 % , 
immune cells . One important mechanism underlying the 93 % , 94 % , 95 % , 96 % , 97 % , 98 % or 99 % identical to SEQ 
potency of antibody therapeutics is the ability of antibody to ID NO : 7 or SEQ ID NO : 8 . For example , the chimeric 
recruit immune cells to a target antigen ( or cell ) . Thus , the polypeptide can comprise a sequence identical to SEQ ID 
Fc region of an antibody is crucial for recruitment of NOs : 3 , 4 , 7 or 8 . 
immunological cells and antibody dependent cytotoxicity 35 In further aspects , a chimeric antibody of the embodi 
( ADCC ) . In particular , the nature of the ADCC response ments further comprises a FcRn - binding peptide , such as 
elicited by antibodies depends on the interaction of the Fc FcRn - binding peptide positioned at the C - terminus of the 
region with receptors ( FcRs ) located on the surface of many chimeric antibody . For example , the FcRn - binding peptide 
cell types . Humans contain five different classes of Fc can comprise the linear peptide of SEO ID NO : 67 or the 
receptors . In addition haplotypes , or genetic variants of 40 cyclic peptide of SEQ ID NO : 68 . 
different FcRs belonging to a particular class are known . The In still a further embodiment there is provided a chimeric 
binding of an antibody to FcRs determines its ability to polypeptide of the embodiments comprises an amino acid 
recruit other immunological cells and the type of cell sequence at least 85 % , 90 % , 91 % 92 % , 93 % , 94 % , 95 % . 
recruited . Hence , the ability to engineer antibodies that can 96 % , 97 % , 98 % or 99 % identical to SEQ ID NO : 7 or SEO 
recruit only certain kinds of cells can be critically important 45 ID NO : 8 . For instance , the chimeric polypeptide can 
for therapy . comprise a sequence identical to SEQ ID NOs : 3 , 4 , 7 or 8 . 
Currently , all antibody therapeutics are of the IgG sub - In a further embodiment there is provided a polynucle 
class . Therapeutic IgG antibodies engage the Fcy class of otide molecule encoding a chimeric polypeptide of the 
receptors via Fc domain interaction on the surface of various embodiments . In certain aspects the polynucleotide further 
blood cells which in turn become activated to kill tumor 50 encodes a promoter , enhancer , polyadenylation sequence , 
cells . For some therapeutics efficacy could be improved by intron , drug selection marker , origin of replication , a 
the additional recruitment of cells that display Fca or Fca reporter or a purification tag . For example , the isolated 
receptors . However , to date , antibody Fc polypeptides have polynucleotide can be comprised in a polynucleotide expres 
not been identified that can bind to additional Fc receptors . sion vector . 
55 In a further aspect , a chimeric polypeptide further com 
SUMMARY OF THE INVENTION prises a mammalian IgG Fc CH1 domain , an IgG VH 
domain and / or a hinge domain . Thus , in some aspects , a 
In a first embodiment there is provided a chimeric poly - recombinant antibody is provided comprising a chimeric 
peptide comprising a CH2 and CH3 domain of a mammalian polypeptide of the embodiments . For example , the recom 
immunoglobulin molecules , wherein the polypeptide binds 60 binant antibody can be a human or humanized antibody . In 
to at least one Fca receptor and at least one Fcy receptor . For yet further aspects , the chimeric antibody is an aglycosy 
example , in certain aspects , a chimeric polypeptide binds to lated antibody . 
a FcyRI or FcyRIIa with a higher affinity than an IgA In certain aspects , an antibody of the embodiments binds 
antibody . In further aspect , a chimeric polypeptide binds to to a cell surface antigen or to a cancer cell antigen . For 
FcaRI with a higher affinity than an IgG antibody . In still a 65 example , in certain aspects , an antibody binds to an EGFR 
further aspect , a chimeric polypeptide binds to a FcyRIIb ( e . g . , HER1 or HER2 ) or VEGFR . In certain aspects , an 
with a lower affinity than an IgG antibody . antibody of the embodiments bind to the same antigen as one 
US 9 , 890 , 216 B2 
of the antibodies selected from Table A . In still a further comprises an amino acid sequence at least about 75 % , 80 % , 
aspect , an antibody of the embodiments comprise CDRs 1 , 85 % , 90 % , 95 % , 98 % or 99 % identical to the heavy chain 
2 , 3 , 4 , 5 and 6 of an antibody of Table A . and / or light chain variable region amino acid sequence of 
In further aspects an antibody according to the embodi the Cetuximab monoclonal antibody . 
ments is coupled to a therapeutic , a reporter , or a targeting 5 As used herein the specification , “ a ” or “ an ” may mean 
moiety . For example , the therapeutic can be a polynucleotide one or more . As used herein in the claim ( s ) , when used in 
( e . g . , a miRNA , a siRNA or an therapeutic gene ) , a peptide , conjunction with the word " comprising ” , the words “ a ” or 
a small molecule , a therapeutic radionuclide , a chemothera - " an " may mean one or more than one . 
peutic , a tumor suppressor , an apoptosis inducer , an enzyme , The use of the term “ or ” in the claims is used to mean 
a second antibody , an siRNA , a hormone , a prodrug , or an 10 " and / or ” unless explicitly indicated to refer to alternatives 
immunostimulant . Examples of reporters include , but are not only or the alternatives are mutually exclusive , although the 
limited to , radionuclides , florophores , MRI contrast agents , disclosure supports a definition that refers to only alterna 
enzymes , dyes or molecules detectable by positron emission tives and " and / or . ” As used herein “ another ” may mean at 
tomography ( PET ) . least a second or more . 
In yet further aspects , an antibody of the embodiments 15 Throughout this application , the term " about " is used to 
comprises one or more of the following : ( a ) decreased indicate that a value includes the inherent variation of error 
affinity for FcYRIIb relative to a wild type IgG1 antibody ; ( b ) for the device , the method being employed to determine the 
increased affinity for FcyRIIa relative to a wild type IgA1 value , or the variation that exists among the study subjects . 
antibody ; ( c ) increased affinity for FcyRI relative to a wild Other objects , features and advantages of the present 
type IgAl antibody ; and / or ( d ) increased affinity for FcaRI 20 invention will become apparent from the following detailed 
relative to a wild type IgG1 antibody . description . It should be understood , however , that the 
In some embodiments , the invention provides a pharma detailed description and the specific examples , while indi 
ceutical composition comprising a chimeric polypeptide or cating preferred embodiments of the invention , are given by 
a recombinant antibody of the embodiments in a pharma - way of illustration only , since various changes and modifi 
ceutically acceptable carrier . 25 cations within the spirit and scope of the invention will 
In a further embodiment there is provided a method of become apparent to those skilled in the art from this detailed 
making a polypeptide comprising : ( a ) expressing a recom description . 
binant polynucleotide encoding a chimeric polypeptide of 
the embodiments in a cell ; and ( b ) obtaining a polypeptide BRIEF DESCRIPTION OF THE DRAWINGS 
expressed by the cell . For example , the cell can be a bacterial 30 
cell , a yeast cell , a ciliate cell , or an insect cell . The following drawings form part of the present specifi 
In still a further embodiment , there is provided a method cation and are included to further demonstrate certain 
treating a subject comprising administering an effective aspects of the present invention . The invention may be better 
amount of an antibody of the embodiment to the subject . In understood by reference to one or more of these drawings in 
certain aspects , the subject has an autoimmune disease or a 35 combination with the detailed description of specific 
cancer . For example , in some aspects , the subject has one of embodiments presented herein . 
the diseases indicated in Table A . Routes for administering FIG . 1A - B — FIG . 1A : Amino acid alignment of mutants 
an antibody include , without limitation , by intravenous B ( SEQ ID NO : 2 ) , C ( SEQ ID NO : 3 ) , and D ( SEQ ID NO : 
administration , intracardiac administration , intradermal 4 ) with wild - type IgG1 ( SEQ ID NO : 1 ) . Black lettering is 
administration , intralesional administration , intrathecal 40 CH2 sequence ; gray lettering is CH3 sequence ; underlined 
administration , intracranial administration , intrapericardial lettering is derived from IgA1 . The additional glycine in 
administration , intraumbilical administration , intraocular mutant D is italicized . FIG . 1B : Wild - type IgA sequence 
administration , intraarterial administration , intraperitoneal with alanine scanning mutations underlined ( SEQ ID NO : 
administration , intraosseous administration , intrahem - 13 ) . 
morhage administration , intratrauma administration , intra - 45 FIG . 2 : Show the results of SDS - PAGE ( 4 % - 20 % ) analy 
tumor administration , subcutaneous administration , intra - sis of chimeric Fc polypeptides of the embodiments . 
muscular administration , intravitreous administration , direct FIG . 3 : Graph shows the binding of chimeric Fc poly 
injection into a normal tissue , or by direct injection into a peptides of the embodiments to FcaRI - GST as assessed by 
tumor . ELISA assay . 
In certain embodiments , there is provided an isolated or 50 FIG . 4 : Graph shows the binding of chimeric Fc poly 
recombinant HER2 - binding antibody wherein the antibody peptides of the embodiments to FcyRI as assessed by ELISA 
comprises a chimeric immunoglobulin heavy constant assay . 
region of the embodiments . In some aspects , a HER2 FIG . 5 : Graph shows the binding of chimeric Fc poly 
binding antibody of the embodiments comprises 1 , 2 , 3 , 4 , peptides of the embodiments to FcyRIIa as assessed by 
5 , or all 6 of the CDRs of the Trastuzumab monoclonal 55 ELISA assay . 
antibody . For example , the HER2 - binding antibody can FIG . 6 : Graph shows the binding of chimeric Fc poly 
comprises an amino acid sequence at least about 75 % , 80 % , peptides of the embodiments to FcyRIIb as assessed by 
85 % , 90 % , 95 % , 98 % or 99 % identical to the heavy chain ELISA assay . 
and / or light chain variable region amino acid sequence of FIG . 7 : Sites mutated to alanine to scan the binding pocket 
the Trastuzumab monoclonal antibody . 60 of FcaRI in IgA for the relative binding contribution of each 
In certain embodiments , there is provided an isolated or position . Picture shows a model of the IgA binding pocket . 
recombinant HER1 - binding antibody wherein the antibody FIG . 8 : Graph shows the results of ELISA analysis of 
comprises a chimeric immunoglobulin heavy constant FcaRI binding to IgA Fc domains containing alanine scan 
region of the embodiments . In some aspects , a HER1 - ning point mutations . Signal has been normalized to a wild 
binding antibody of the embodiments comprises 1 , 2 , 3 , 4 , 65 type IgA Fc domain . 
5 , or all 6 of the CDRs of the Cetuximab monoclonal FIG . 9 : Figure shows results of a 4 - 20 % SDS - PAGE 
antibody . For example , the HER1 - binding antibody can separation of full length antibodies expressed from 
US 9 , 890 , 216 B2 
6 
HEK293F cells . Lane A trastuzumab IgG , Lane B trastu tion . However , IgG antibodies do not engage the FcaRI 
zumab IgG N297D , Lane C trastuzumab MutD , Lane D receptor and hence poorly activate neutrophils and other 
trastuzmab IgA granulocytes . 
FIG . 10 : SPR kinetic analysis of MutD binding to soluble Despite their potential promise , use of the IgA antibody 
FcYRI as fit by a 1 : 1 Langmuir isotherm model . 5 isotype to exploit the potent inflammatory effects of FcaRI 
FIG . 11 : SPR kinetic analysis of MutD binding to soluble in a therapeutic setting has so far been disfavored due to low 
FcaRI - GST as fit by a 2 : 1 bivalent analyte model . expression yields and expensive purification schemes 
FIG . 12 : SPR kinetic analysis of IgA binding to soluble required for IgA antibodies . Further , IgA antibodies do not 
FcaRI - GST as fit by a 2 : 1 bivalent analyte model . display the favorable therapeutic functions that IgG anti 
FIG . 13 : SPR equilibrium analysis of IgG binding to 10 bodies do . Combination therapy of IgA with IgG is likewise 
soluble monmeric FcYRIIAR131 as fit by a 1 : 1 Langmuir undesirable both due to regulatory and cost concerns and 
isotherm model . also due to the blocking of neutrophils activated via FcaRI 
FIG . 14 : SPR equilibrium analysis of MutD binding to action by the engagement of the FcyRIIb receptor by IgG . 
soluble monmeric FcyRIIaR131 as fit by a 1 : 1 Langmuir The polypeptides and antibodies provided herein address 
isotherm model 15 these issues by providing Fc domains that are able to bind 
FIG . 15 : SPR equilibrium analysis of IgG binding to both Fca and Fcy receptors . Specifically , an IgG1 antibody 
soluble monmeric FcyRIIb as fit by a 1 : 1 Langmuir isotherm Fc domain has been engineered to introduce de novo binding 
model . to the IgA FcaRI receptor while retaining existing affinity 
FIG . 16 : SPR equilibrium analysis of MutD binding to for FcyRs . For example , chimeric Fc domains that comprise 
soluble monmeric FcyRIIb as fit by a 1 : 1 Langmuir isotherm 20 sequences from both IgG and IgA Fc ' s are shown to have 
model . significant FcaRI binding ( see FIG . 3 ) . Nonetheless , the 
FIG . 17 : Graphs show neutrophil killing of Her2 + SKBR - 3 polypeptides retain significant binding to FcyRI and FcyRIIa 
cells by ADCC using IgG , aglycosylated IgG N297D , IgA ( FIGS . 4 - 5 ) . Perhaps most importantly , the new chimeric Fc 
and MutD trastuzumab variants . Cells were seeded at a ratio polypeptides retain only limited affinity for FcyRIIb , a 
of 80 : 1 neutrophils to tumor cells . Bars in the graph indicate 25 receptor that can block activation of key effect cells such as 
the results with decreasing concentration of the indicated neutrophils ( FIG . 6 ) . Moreover , chimeric antibodies could 
antibodies ( 20 , 2 or 0 . 2 ug / ml ) from left to right . be further modified by the additional of an FcRn binding 
FIG . 18 : Graph show the results of ELISA analysis of peptide ( FIG . 18 ) , a modification that may increase serum 
FcRN binding to MutD fusions with cyclic or linear C - ter - half life of the molecules . Thus , the new chimeric Fc 
minus peptides at pH 7 . 4 and pH 5 . 8 . 30 polypeptides and antibodies that incorporate the polypep 
FIG . 19 : An example alignment showing various mam - tides offer a broader range of effector function relative to 
malian IgA Fc domains with the locations of the CH2 al either IgG or IgA alone , which could greatly improve the 
loop and CH3 domains indicated . Sequences in the align - efficacy of new antibody therapeutics . Moreover , the new 
ment from top to bottom include those from the human IgA1 chimeric Fc polypeptides can be used to replace the Fc 
Fc ( SEQ ID NO : 77 ) ; human IgA2 Fc ( SEQ ID NO : 78 ) ; 35 domains of existing antibody therapeutics , thereby rendering 
mouse IgA Fc ( SEQ ID NO : 79 ) ; rabbit IgA Fc ( SEQ ID NO : them more effective . This effect is exemplified in studies 
80 ) ; gorilla IgA Fc ( SEQ ID NO : 81 ) ; and pig IgA Fc ( SEQ presented here . For example , when a chimeric Fc domain 
ID NO : 82 ) . ( MutD ) was fused to trastuzumab the new chimeric antibody 
was able to mediate neutrophil killing of Her expressing 
DESCRIPTION OF ILLUSTRATIVE 40 cells with high efficiency ( see FIG . 17 ) . 
EMBODIMENTS 
II . IgA and FcaRI 
I . The Present Invention 
Monomeric IgA is the second most abundant immuno 
Antibody - based therapeutics have recently been approved 45 globulin in human serum after the IgG isotype . IgA anti 
for treatment of a wide range of diseases from cancer to bodies , typically implicated in mucosal surface defense , are 
autoimmune disease ( see , e . g . , Table A ) . Recently , recom - represented in higher serum concentrations in humans than 
binant antibodies have even been developed for treatment of in the sera of other animal species . Together , the two IgA 
infectious disease . However , the efficacy of most antibody - allotypes comprise up to 25 % of human serum immuno 
based therapeutics is dependent on the effector function of 50 globulins . Also unique to humans is the high proportion of 
cells and factors that bind to the antibodies , such as comple - monomeric serum IgA ( ~ 90 % ) as opposed to J chain linked 
ment . For example , antibodies that target specific cell types dimeric forms ( Woof and Kerr , 2006 ) . 
are currently used as anticancer therapies , but many anti - IgA binds selectively to the FcaRi ( CD89 ) receptor , 
bodies are either not directly toxic to the cancer cells or have which is constitutively expressed on cells of the myeloid 
low cytotoxicity . Thus , despite the targeting specificity of 55 lineage , including neutrophils , macrophages , and eosino 
such antibodies , many fail to exhibit sufficient effect ( e . g . , phils , in humans . Membrane anchored Fcari is found 
cell killing ) on target cells . expressed with or without association to the Fcy signaling 
In contrast to IgG , which have been the only type of chain . If unassociated , FcaRI internalizes and recycles IgA 
therapeutic antibody used to date , antibodies that belong to to the cell surface . However , even with this recycling 
the IgA class engage the widely expressed FcaRI receptor 60 mechanism , the circulation half - life is significantly less than 
on neutrophils . These cells comprise the greatest fraction of that of IgG at 5 . 9 days for serum IgA1 and 4 . 5 days for 
innate effector cells found in circulation and can activate serum IgA2 ( Morell et al . , 1973 ) . On the other hand , 
potent inflammatory action when FcaRI is cross - linked by association of IgA chains with CD89 is essential for IgA 
IgA immune complexes . Both antibody dependent cell facilitated Ag presentation , oxidative burst , cytokine release , 
mediated cytotoxicity ( ADCC ) ( oxidative burst , degranula - 65 and tumor killing ( Jacob et al . , 2008 ) . There are at least ten 
tion ) and antibody dependent cell mediated phagocytosis spliced isoforms of CD89 reported , the majority of which 
( ADCP ) responses have been observed upon FcaRI activa - have undefined functions ( Qian et al . , 2008 ) . Despite sig 
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nificant effort , a murine homologue of this receptor has not position of an IgG CH3 domain , such as a human IgG1 . 
been identified . It has been suggested that mice lost the Thus , in certain specific aspects , a chimeric polypeptide of 
FcaR1 gene during a translocation event from chromosome the embodiments comprises a CH3 domain that is 85 % , 
7 to the X chromosome ( Woof and Kerr , 2004 ) . IgA immune 90 % , 91 % 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , 99 % or 
complexes have been reported to induce strong inflamma - 5 100 % identical to a CH3 domain ( positions 336 - 443 ; SEO 
tory responses and demonstrate efficient tumor killing by ID NO : 9 ) of a human IgA1 . 
neutrophil recruitment upon binding FcaRI ( van Egmond et In still further aspects , a chimeric polypeptide of the 
al . , 2001 ; Stockmeyer et al . , 2000 ) . In fact , tumor killing by embodiments comprises a CH3 domain that is 85 % , 90 % , 
IgA activation of the FcaR1 receptor on neutrophils has 91 % , 92 % , 93 % , 94 % or 95 % , identical to a CH3 domain 
been shown to be more potent than IgG tumor killing by 10 ( positions 336 - 443 ; SEQ ID NO : 10 ) of a human IgG1 and 
activation of FcyR1 and co - activation of both receptors by comprising 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 or 10 amino acid positions 
bispecific antibodies showed an additive effect in tumor that are substituted with the amino at a corresponding 
treatment . However , therapeutic dosing with full - length IgA position of an IgA CH3 domain , such as a human IgA1 . For 
and IgG in combination was less successful as the Fc domain example , the CH3 domain of a chimeric polypeptide can 
of IgGi binds FcyRIIb , an inhibitory receptor , which 15 comprise an amino acid substitution corresponding to F443 , 
reduced the tumor killing efficiency of IgA . Development of E437 , M433 , E389 and / or R382 , as shown in FIG . 1B . 
an IgA Fc domain engineered to bind the FcyR1 receptor has CH2 Domain 
the potential to exploit both tumor killing pathways without A chimeric polypeptide of the embodiments , in certain 
activation of inhibitory functions . aspects , comprises a chimeric CH2 from a mammalian 
IgA antibodies have not yet received attention for thera - 20 immunoglobulin . Preferably , the chimeric CH2 domain 
peutic applications partially because their production is comprises chimeric domains of human IgG and IgA CH2 
costly and inefficient but also because their half - life in serum domains . For example , the CH2 domain can comprise a IgG 
is shorter than that of IgG antibodies . Part of the concern in CH2 domain having an al and / or a2 loop domain from an 
IgA expression is the heavily glycosylated hinge region that IgA . In some specific aspects , a chimeric CH2 domain 
includes up to five O - linked glycosylation sites . Glycosy - 25 comprises a CH2 domain from a human IgG1 having an al 
lation not only impacts the expression level but also intro - and / or a2 loop domain from a human IgA1 . In still further 
duces the potential for large glycan heterogeneity during aspects a chimeric CH2 domain comprises a CH2 domain 
production . By engineering FcaRI binding into an IgG from a human IgG1 having 1 , 2 , 3 , 4 or 5 amino acids 
molecule , many of these concerns can be alleviated . To substituted for an amino acid at a corresponding position in 
further define the FcaRI binding pocket in IgA1 , point 30 an al and / or a2 loop domain from a human IgA1 . Thus , in 
mutations were generated in either of two interdomain loops some aspects , a chimeric CH2 domain of the embodiments 
( Leu - 257 - Gly - 259 in the CH2 domain ; Pro - 440 - Phe - 443 in is at least about 85 % , 90 % , 91 % 92 % 93 % , 94 % , 95 % . 
the CH3 domain ) . Each substitution , with the exception of 96 % , 97 % , 98 % , 99 % or 100 % identical to the CH2 of the 
G259R , resulted in greatly ablated FcaRI binding . “ Mutant C ” or “ Mutant D ” polypeptide ( SEQ ID NOs : 11 
35 and 12 , respectively ) . In still further aspects , a CH2 domain 
II . Modified Proteins and Polypeptides of the embodiment may comprise 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 or 
10 amino acid positions that is a substituted with the amino 
Embodiments concerns modified polypeptides , in particu - at a corresponding position of an IgA CH2 domain , such as 
lar polypeptides comprising chimeric Fc domains that confer a human IgA1 . For example , the CH2 domain of a chimeric 
binding to both IgGy and IgGa receptors . Preferably the 40 polypeptide can comprise an amino acid substitution corre 
chimeric polypeptides have limited binding affinity for sponding to N316 , E313 and / or L258 , as shown in FIG . 1B . 
IgGyIIb . Polypeptides of the embodiments comprise por - In some aspects , a chimeric CH2 domain of the embodi 
tions of an IgG Fc domain ( e . g . , an IgG1 Fc ) and portions ments can comprise a conservative amino acid insertion , 
of an IgA Fc domain . In certain aspects , a chimeric poly - deletion of substitution as further outlined below . For 
peptide comprises a Fc CH2 and CH3 domain sequence that 45 instance the chimeric CH2 domain can comprise an amino 
is composed of chimeric domains of human IgA ( e . g . , IgA1 acid insertion to maintain the relative lengths of domains 
or IgA2 , NCBI accession nos . P01876 . 2 and P01877 . 3 , between IgG and IgA , as was done in the case of the " Mutant 
respectively incorporated herein by reference ; see also SEQ D " polypeptide where a Gly was inserted after the IgA al 
ID NO : 9 ) and human IgG ( e . g . , IgG1 , IgG2 , IgG3 or IgG4 , loop sequence . 
NCBI accession nos . P01857 . 1 ; P01859 . 2 ; PO1860 . 2 ; and 50 Additional Domains 
P01861 . 1 , respectively , incorporated herein by reference ) . In certain aspects , a chimeric polypeptide of the embodi 
As used herein , numbering of amino acid position in a ments further comprises a CH1 and / or hinge domain from a 
chimeric polypeptide refers to the standard nomenclature set mammalian immunoglobulin . Preferably the CH1 and / or 
forth , e . g . , in Kabat et al . , 1991 , incorporated herein by hinge domain are from a human IgG polypeptide . For 
reference . 55 example , the CH1 and / or hinge domain can be a at least 
CH3 Domain about 85 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 
In certain aspects , a chimeric polypeptide of the embodi - 98 % , 99 % or 100 % identical to the CH1 and / or hinge 
ments comprises a CH3 from a mammalian immunoglobu - domain of a human IgG1 , IgG2 , IgG3 or IgG4 ( see , e . g . , 
lin . Preferably the CH3 is substantially homologous to a NCBI accession nos . P01857 . 1 ; P01859 . 2 ; P01860 . 2 ; and 
human IgA CH3 domain . For example , the CH3 domain can 60 P01861 . 1 , incorporated herein by reference ) . In some 
be at least about 85 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , aspects , a CH1 domain of the embodiments can comprise a 
96 % , 97 % , 98 % , 99 % or 100 % identical to the CH3 of a conservative amino acid insertion , deletion of substitution as 
human IgA1 or IgA2 ( see , e . g . , NCBI accession nos outlined below . 
P01876 . 2 and P01877 . 3 , incorporated herein by reference ) . In still further aspects a chimeric polypeptide of the 
In further aspects , a CH3 domain of the embodiment may 65 embodiments further comprises a VH domain . In further 
comprise 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 or 10 amino acid positions aspects , a chimeric polypeptide is further associated with 
that are substituted with the amino at a corresponding ( e . g . , via disulfides bonds ) an immunoglobulin light chain . 
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Thus , in some aspects , a chimeric polypeptide of the typically involves the addition of at least one residue in the 
embodiments comprises an antibody . polypeptide . This may include the insertion of a targeting 
It is further contemplated that additional modifications polypeptide or simply a single residue . Terminal additions , 
could be made to a chimeric polypeptide of the embodi - called fusion proteins , are discussed below . 
ments . For example , a modified chimeric polypeptide can be 5 It also will be understood that amino acid and nucleic acid 
made that exhibits at least one functional activity that is sequences may include additional residues , such as addi 
comparable to the unmodified version , yet the modified tional N - or C - terminal amino acids or 5 ' or 3 ' sequences , 
protein or polypeptide possesses an additional advantage and yet still be essentially as set forth in one of the sequences 
over the unmodified version , such as cheaper to production , disclosed herein , so long as the sequence meets the criteria 
eliciting fewer side effects , and / or having better or longer 10 set forth above , including the maintenance of biological 
efficacy or bioavailability . Thus , when the present applica - protein activity where protein expression is concerned . The 
tion refers to the function or activity of a “ modified chimeric addition of terminal sequences particularly applies to nucleic 
polypeptide ” one of ordinary skill in the art would under - acid sequences that may , for example , include various 
stand that this includes , for example , polypeptide that 1 ) non - coding sequences flanking either of the 5 ' or 3 ' portions 
performs at least one of the same activities or has at least one 15 of the coding region or may include various internal 
of the same specificities as the unmodified polypeptide , but sequences , i . e . , introns , which are known to occur within 
that may have a different level of another activity or speci genes . Thus , in certain , aspects a chimeric polypeptide of the 
ficity ; and 2 ) possesses an additional advantage over the embodiments comprises from N - to C - terminus : a VH 
unmodified polypeptide . Determination of activity may be domain - CH1 domain - hinge domain - chimeric CH2 
achieved using assays familiar to those of skill in the art , 20 domain - a CH3 domain ( e . g . , an IgA CH3 domain ) . 
particularly with respect to the protein ' s activity , and may The following is a discussion on strategies for changing of 
include for comparison purposes , for example , the use of the amino acids of a polypeptide to create an equivalent , or 
native and / or recombinant versions of either the modified or even an improved , second - generation molecule . For 
unmodified protein or polypeptide . In addition to the modi - example , certain amino acids may be substituted for other 
fied polypeptides discussed herein , embodiments may 25 amino acids in a polypeptide structure with or without 
involve domains , polypeptides , described in WO 2008 / appreciable loss of interactive binding capacity with struc 
137475 , which is hereby specifically incorporated by refer - tures such as , for example , binding sites to substrate mol 
ence . ecules . This is especially possible in polypeptides that have 
Modified chimeric polypeptides may possess deletions a well know structure , such as antibody polypeptides ( see , 
and / or substitutions of amino acids ; thus , a protein with a 30 e . g . , in Kabat et al . , 1991 ) . 
deletion , a protein with a substitution , and a protein with a In making changes , in some cases , the hydropathic index 
deletion and a substitution are modified proteins . In some of amino acids may be considered . The importance of the 
embodiments these modified proteins may further include hydropathic amino acid index in conferring interactive bio 
insertions or added amino acids , such as with fusion proteins logic function on a protein is generally understood in the art 
or proteins with linkers , for example ( see , e . g . , the Gly 35 ( Kyte & Doolittle , 1982 ) . It is accepted that the relative 
insertion in “ Mutant D ” polypeptide ) . A " modified deleted hydropathic character of the amino acid contributes to the 
polypeptide " lacks one or more residues of the native secondary structure of the resultant protein , which in turn 
protein , but possesses the specificity and / or activity of the defines the interaction of the protein with other molecules , 
native polypeptide . A “ modified deleted polypeptide ” may for example , enzymes , substrates , receptors , DNA , antibod 
also have reduced immunogenicity or antigenicity . An 40 ies , antigens , and the like . 
example of a modified deleted polypeptide is one that has an It also is understood in the art that the substitution of like 
amino acid residue deleted from at least one antigenic amino acids can be made effectively on the basis of hydro 
region — that is , a region of the protein determined to be philicity . U . S . Pat . No . 4 , 554 , 101 , incorporated herein by 
antigenic in a particular organism , such as the type of reference , states that the greatest local average hydrophilic 
organism that may be administered the modified protein . 45 ity of a protein , as governed by the hydrophilicity of its 
Substitutional or replacement variants typically contain adjacent amino acids , correlates with a biological property 
the exchange of one amino acid for another at one or more of the protein . As detailed in U . S . Pat . No . 4 , 554 , 101 , the 
sites within the polypeptide and may be designed to modu - following hydrophilicity values have been assigned to amino 
late one or more properties of the polypeptide , particularly acid residues : arginine ( + 3 . 0 ) ; lysine ( + 3 . 0 ) ; aspartate 
its effector functions and / or bioavailability . Certain specific 50 ( + 3 . 0 : 1 ) ; glutamate ( + 3 . 0 : 1 ) ; serine ( + 0 . 3 ) ; asparagine 
amino acid exchanges in chimeric polypeptides of the ( + 0 . 2 ) ; glutamine ( + 0 . 2 ) ; glycine ( 0 ) ; threonine ( - 0 . 4 ) ; pro 
embodiments are detailed above . Further substitutions may line ( - 0 . 5 + 1 ) ; alanine ( - 0 . 5 ) ; histidine ( - 0 . 5 ) ; cysteine 
or may not be conservative , that is , one amino acid is ( - 1 . 0 ) ; methionine ( - 1 . 3 ) ; valine ( - 1 . 5 ) ; leucine ( - 1 . 8 ) ; 
replaced with one of similar shape and charge . Conservative isoleucine ( - 1 . 8 ) ; tyrosine ( - 2 . 3 ) ; phenylalanine ( - 2 . 5 ) ; 
substitutions are well known in the art and include , for 55 tryptophan ( - 3 . 4 ) . 
example , the changes of : alanine to serine ; arginine to It is understood that an amino acid can be substituted for 
lysine ; asparagine to glutamine or histidine ; aspartate to another having a similar hydrophilicity value and still pro 
glutamate ; cysteine to serine ; glutamine to asparagine ; glu - duce a biologically equivalent and immunologically equiva 
tamate to aspartate ; glycine to proline ; histidine to aspara - lent protein . In such changes , the substitution of amino acids 
gine or glutamine ; isoleucine to leucine or valine ; leucine to 60 whose hydrophilicity values are within + 2 is preferred , those 
valine or isoleucine ; lysine to arginine ; methionine to leu that are within + 1 are particularly preferred , and those within 
cine or isoleucine ; phenylalanine to tyrosine , leucine or + 0 . 5 are even more particularly preferred . 
methionine ; serine to threonine ; threonine to serine ; trypto - As outlined above , amino acid substitutions generally are 
phan to tyrosine ; tyrosine to tryptophan or phenylalanine ; based on the relative similarity of the amino acid side - chain 
and valine to isoleucine or leucine . 65 substituents , for example , their hydrophobicity , hydrophi 
In addition to a deletion or substitution , a modified licity , charge , size , and the like . Exemplary substitutions that 
polypeptide may possess an insertion of residues , which take into consideration the various foregoing characteristics 
11 
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are well known to those of skill in the art and include : described in Maniatis et al . , 1988 and Ausubel et al . , 1994 , 
arginine and lysine ; glutamate and aspartate ; serine and both of which references are incorporated herein by refer 
threonine ; glutamine and asparagine ; and valine , leucine and ence . 
isoleucine . The term " expression vector ” refers to a vector containing 
5 a nucleic acid sequence coding for at least part of a gene 
III . Nucleic Acid - Based Expression Systems product capable of being transcribed . In some cases , RNA 
molecules are then translated into a polypeptide ( e . g . , a 
Nucleic acid - based expression systems may find use , in chimeric polypeptide ) . Expression vectors can contain a 
certain embodiments of the invention , for the expression of variety of control sequences , ” which refer to nucleic acid 
recombinant polypeptides and antibodies of the embodi - 10 sequences necessary for the transcription and possibly trans 
lation of an operably linked coding sequence in a particular ments . Thus , certain aspects of the embodiments concern 
polynucleotide that encode a chimeric polypeptide of the host organism . In addition to control sequences that govern transcription and translation , vectors and expression vectors embodiments . Below is a discussion of polynucleotide vec may contain nucleic acid sequences that serve other func tor for expression of chimeric polypeptides and methods for 15 tions as well and are described infra . production of the polypeptides . As used herein the terms 1 . Promoters and Enhancers " polynucleotide ” and “ nucleic acids ” are used interchange A “ promoter " is a control sequence that is a region of a ably . nucleic acid sequence at which initiation and rate of tran A . Methods of Polynucleotide Delivery scription are controlled . It may contain genetic elements at 
Certain aspects of the embodiments may comprise deliv - 20 which regulatory proteins and molecules may bind such as 
ery of polynucleotide to target cells ( e . g . , host cells ) . For RNA polymerase and other transcription factors . The 
example , bacterial , yeast or mammalian host cells may be phrases “ operatively positioned , ” " operatively linked , " 
transformed with nucleic acids encoding chimeric polypep - " under control , ” and “ under transcriptional control ” mean 
tides . Suitable methods for nucleic acid delivery for trans - that a promoter is in a correct functional location and / or 
formation of a cell are believed to include virtually any 25 orientation in relation to a nucleic acid sequence to control 
method by which a nucleic acid ( e . g . , DNA ) can be intro - transcriptional initiation and / or expression of that sequence . 
duced into such a cell , or even an organelle thereof . Such A promoter may or may not be used in conjunction with an 
methods include , but are not limited to , direct delivery of " enhancer , ” which refers to a cis - acting regulatory sequence 
DNA such as by injection ( U . S . Pat . Nos . 5 , 994 , 624 , 5 , 981 , involved in the transcriptional activation of a nucleic acid 
274 , 5 , 945 , 100 , 5 , 780 , 448 , 5 , 736 , 524 , 5 , 702 , 932 , 5 , 656 . 610 . 30 sequence . 
5 , 589 , 466 and 5 , 580 , 859 , each incorporated herein by ref A promoter may be one naturally associated with a gene 
erence ) , including microinjection ( Harland and Weintraub , or sequence , as may be obtained by isolating the 5 ' non or sequence , as may be obtained by isolating the shon 
1985 ; U . S . Pat . No . 5 , 789 , 215 , incorporated herein by coding sequences located upstream of the coding segment 
reference ) ; by electroporation ( U . S . Pat . No . 5 , 384 , 253 , and / or exon . Such a promoter can be referred to as " endog 35 enous . ” Similarly , an enhancer may be one naturally asso incorporated herein by reference ) ; by calcium phosphate ciated with a nucleic acid sequence , located either down precipitation ( Graham and Van Der Eb , 1973 ; Chen and stream or upstream of that sequence . Alternatively , certain Okayama , 1987 ; Rippe et al . , 1990 ) ; by using DEAE advantages will be gained by positioning the coding nucleic 
dextran followed by polyethylene glycol ( Gopal , 1985 ) ; by acid segment under the control of a recombinant or heter 
direct sonic loading ( Fechheimer et al . , 1987 ) ; by liposome 40 ologous promoter , which refers to a promoter that is not 
mediated transfection ( Nicolau and Sene , 1982 ; Fraley et al . , normally associated with a nucleic acid sequence in its 
1979 ; Nicolau et al . , 1987 ; Wong et al . , 1980 ; Kaneda et al . , natural environment . A recombinant or heterologous 
1989 ; Kato et al . , 1991 ) ; by microprojectile bombardment enhancer refers also to an enhancer not normally associated 
( PCT Application Nos . WO 94 / 09699 and 95 / 06128 ; U . S . with a nucleic acid sequence in its natural environment . 
Pat . Nos . 5 , 610 , 042 ; 5 , 322 , 783 , 5 , 563 , 055 , 5 , 550 , 318 , 45 Such promoters or enhancers may include promoters or 
5 , 538 , 877 and 5 , 538 , 880 , and each incorporated herein by enhancers of other genes , and promoters or enhancers iso 
reference ) ; or by agitation with silicon carbide fibers ( Kae - lated from any other prokaryotic cell , and promoters or 
ppler et al . , 1990 ; U . S . Pat . Nos . 5 , 302 , 523 and 5 , 464 , 765 , enhancers not " naturally occurring , ” i . e . , containing differ 
each incorporated herein by reference ) ; by desiccation ent elements of different transcriptional regulatory regions , 
inhibition - mediated DNA uptake ( Potrykus et al . , 1985 ) . 50 and / or mutations that alter expression . In addition to pro 
Through the application of techniques such as these , cells ducing nucleic acid sequences of promoters and enhancers 
may be stably or transiently transformed . synthetically , sequences may be produced using recombi 
B . Vectors nant cloning and / or nucleic acid amplification technology , 
Vectors may find use with the current invention , for including PCRTM , in connection with the compositions dis 
example , in the transformation of a host cells with a nucleic 55 closed herein ( see U . S . Pat . No . 4 , 683 , 202 , U . S . Pat . No . 
acid sequence encoding a chimeric polypeptides . The term 5 , 928 , 906 , each incorporated herein by reference ) . 
“ vector ” is used to refer to a carrier nucleic acid molecule Naturally , it will be important to employ a promoter 
into which a nucleic acid sequence can be inserted for and / or enhancer that effectively directs the expression of the 
introduction into a cell where it can be replicated . A nucleic DNA segment in the cell type chosen for expression . One 
acid sequence can be " exogenous , " or " heterologous ” , 60 example of such promoter that may be used with the 
which means that it is foreign to the cell into which the invention is the E . coli arabinose or T7 promoter . Those of 
vector is being introduced or that the sequence is homolo - skill in the art of molecular biology generally are familiar 
gous to a sequence in the cell but in a position within the host with the use of promoters , enhancers , and cell type combi 
cell nucleic acid in which the sequence is ordinarily not nations for protein expression , for example , see Sambrook et 
found . Vectors include plasmids , cosmids and viruses ( e . g . , 65 al . ( 1989 ) , incorporated herein by reference . The promoters 
bacteriophage ) . One of skill in the art may construct a vector employed may be constitutive , tissue - specific , inducible , 
through standard recombinant techniques , which are and / or useful under the appropriate conditions to direct high 
13 
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level expression of the introduced DNA segment , such as is marker is one that confers a property that allows for selec 
advantageous in the large - scale production of recombinant tion . A positive selectable marker is one in which the 
proteins and / or peptides . The promoter may be heterologous presence of the marker allows for its selection , while a 
or endogenous . negative selectable marker is one in which its presence 
2 . Initiation Signals and Internal Ribosome Binding Sites 5 prevents its selection . An example of a positive selectable 
A specific initiation signal also may be required for marker is a drug resistance marker . 
efficient translation of coding sequences . These signals Usually the inclusion of a drug selection marker aids in include the ATG initiation codon or adjacent sequences . quences the cloning and identification of transformants , for example , Exogenous translational control signals , including the ATG genes that confer resistance to neomycin , puromycin , hygro initiation codon , may need to be provided . One of ordinary 10 
skill in the art would readily be capable of determining this mycin , DHFR , GPT , zeocin and histidinol are useful select able markers . In addition to markers conferring a phenotype and providing the necessary signals . It is well known that the 
initiation codon must be “ in - frame ” with the reading frame that allows for the discrimination of transformants based on 
of the desired coding sequence to ensure translation of the the implementation of conditions , other types of markers 
entire insert . The exogenous translational control signals and 15 including screenable markers such as GFP , whose basis is 
initiation codons can be either natural or synthetic . The colorimetric analysis , are also contemplated . Alternatively , 
efficiency of expression may be enhanced by the inclusion of screenable enzymes such as chloramphenicol acetyltrans 
appropriate transcription enhancer elements . ferase ( CAT ) may be utilized . One of skill in the art would 
3 . Multiple Cloning Sites also know how to employ immunologic markers , possibly in 
Vectors can include a multiple cloning site ( MCS ) , which 20 conjunction with FACS analysis . The marker used is not 
is a nucleic acid region that contains multiple restriction believed to be important , so long as it is capable of being 
enzyme sites , any of which can be used in conjunction with expressed simultaneously with the nucleic acid encoding a 
standard recombinant technology to digest the vector ( see gene product . Further examples of selectable and screenable 
Carbonelli et al . , 1999 , Levenson et al . , 1998 , and Cocea , markers are well known to one of skill in the art . 
1997 , incorporated herein by reference . ) “ Restriction 25 C . Host Cells 
enzyme digestion ” refers to catalytic cleavage of a nucleic In the context of expressing a chimeric polypeptide , “ host 
acid molecule with an enzyme that functions only at specific cell ” refers to a cell , of any transformable organism that is 
locations in a nucleic acid molecule . Many of these restric capable of replicating a vector and / or expressing a heter 
tion enzymes are commercially available . Use of such ologous gene encoded by a vector . A host cell can , and has 
enzymes is understood by those of skill in the art . Fre - 30 been , used as a recipient for vectors . A host cell may be quently , a vector is linearized or fragmented using a restric “ transfected ” or “ transformed , ” which refers to a process by tion enzyme that cuts within the MCS to enable exogenous which exogenous nucleic acid is transferred or introduced sequences to be ligated to the vector . “ Ligation ” refers to the 
process of forming phosphodiester bonds between two into the host cell . A transformed cell includes the primary 
nucleic acid fragments , which may or may not be contiguous 35 5 subject cell and its progeny . Host cells for use according to 
with each other . Techniques involving restriction enzymes the embodiments include , without limitation , insect cells , 
and ligation reactions are well known to those of skill in the mammalian cell ( e . g . , CHO cells ) , ciliate cells , yeast cells 
art of recombinant technology . and bacterial cells . 
4 . Termination Signals For example , numerous prokaryotic cell lines and cultures 
The vectors or constructs prepared in accordance with the 40 are available for use as a host cell , and they can be obtained 
present invention will generally comprise at least one ter - through the American Type Culture Collection ( ATCC ) , 
mination signal . A " termination signal ” or “ terminator " is which is an organization that serves as an archive for living 
comprised of the DNA sequences involved in specific ter - cultures and genetic materials ( www . atcc . org ) . An appropri 
mination of an RNA transcript by an RNA polymerase . ate host can be determined by one of skill in the art based on 
Thus , in certain embodiments , a termination signal that ends 45 the vector backbone and the desired result . A plasmid or 
the production of an RNA transcript is contemplated . A cosmid , for example , can be introduced into a prokaryote 
terminator may be necessary in vivo to achieve desirable host cell for replication of many vectors . Bacterial cells used 
message levels . as host cells for vector replication and / or expression include 
Terminators contemplated for use in the invention include DH5A , JM109 , and KC8 , as well as a number of commer 
any known terminator of transcription described herein or 50 cially available bacterial hosts such as SURE® Competent 
known to one of ordinary skill in the art , including but not Cells and SOLOPACKTM Gold Cells ( STRATAGENE , La Jolla ) . 
limited to , for example , rhp dependent or rho independent Alternatively , bacterial cells such as E . coli LE392 could be 
terminators . In certain embodiments , the termination signal used as host cells for bacteriophage . 
may be a lack of transcribable or translatable sequence , such Many host cells from various cell types and organisms are 
as due to a sequence truncation . 55 available and would be known to one of skill in the art . 
5 . Origins of Replication Similarly , a viral vector may be used in conjunction with a 
In order to propagate a vector in a host cell , it may contain prokaryotic host cell , particularly one that is permissive for 
one or more origins of replication sites ( often termed “ ori ” ) , replication or expression of the vector . Some vectors may 
which is a specific nucleic acid sequence at which replica - employ control sequences that allow it to be replicated 
tion is initiated . 60 and / or expressed in both prokaryotic and eukaryotic cells . 
6 . Selectable and Screenable Markers One of skill in the art would further understand the condi 
In certain embodiments of the invention , cells containing tions under which to incubate all of the above described host 
a nucleic acid construct of the present invention may be cells to maintain them and to permit replication of a vector . 
identified in vitro or in vivo by including a marker in the Also understood and known are techniques and conditions 
expression vector . Such markers would confer an identifi - 65 that would allow large - scale production of vectors , as well 
able change to the cell permitting easy identification of cells as production of the nucleic acids and chimeric polypeptides 
containing the expression vector . Generally , a selectable of the embodiments . 
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TABLE A - continued 
Therapeutic antibodies : 
Indication 
Melanoma 
Chronic lymphocytic leukemia 
Colorectal cancer 
HER2 - positive metastatic breast cancer 
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D . Expression Systems 
Numerous expression systems exist that comprise at least 
a part or all of the compositions discussed above . Prokary 
ote - and / or eukaryote - based systems can be employed for Antibody 
use with the present invention to produce nucleic acid 5 Ipilimumab sequences , or their cognate polypeptides , proteins and pep Ofatumumab 
tides . Many such systems are commercially and widely Panitumumab 
available . Pertuzumab 
Rituximab The insect cell / baculovirus system can produce a high 10 Tositumomab level of protein expression of a heterologous nucleic acid Trastuzumab 
segment , such as described in U . S . Pat . Nos . 5 , 871 , 986 , 
4 , 879 , 236 , both herein incorporated by reference , and which 
Adalimumab can be bought , for example , under the name MAXBAC® Basiliximab 2 . 0 from INVITROGEN® and BACPACKTM BACULOVI N® and BACPACKIM BACULOVI - 15 Belimumab 
RUS EXPRESSION SYSTEM FROM CLONTECH® . Canakinumab 
In addition to the disclosed expression systems of the Certolizumab 
invention , other examples of expression systems include Daclizumab 
STRATAGENE® ' s COMPLETE CONTROLTM Inducible Golimumab 
Mammalian Expression System , which involves a synthetic 
ecdysone - inducible receptor , or its pET Expression System , 20 Infliximab Mepolizumab an E . coli expression system . Another example of an induc Muromonab ible expression system is available from INVITROGEN® , CD3 
which carries the T - REXTM ( tetracycline - regulated expres Natalizumab 
sion ) System , an inducible mammalian expression system Omalizumab 
J 25 Tocilizumab that uses the full - length CMV promoter . INVITROGEN® ( or Atlizumab ) also provides a yeast expression system called the Pichia Ustekinumab 
methanolica Expression System , which is designed for 
high - level production of recombinant proteins in the meth 
Ranibizumab ylotrophic yeast Pichia methanolica . One of skill in the art 30 Abciximab would know how to express a vector , such as an expression Eculizumab 
construct , to produce a nucleic acid sequence or its cognate Palivizumab 
polypeptide , protein , or peptide . 
15 
Several auto - immune disorders 
Transplant rejection 
Systemic lupus erythematosus 
Cryopyrin - associated periodic syndrome ( CAPS ) 
Crohn ' s disease , rheumatoid arthritis 
pegol 
Transplant rejection 
Rheumatoid arthritis , Psoriatic arthritis , Ankylosing 
spondylitis 
Several auto - immune disorders 
Asthma , white blood cell diseases 
Transplant rejection 
Multiple sclerosis , Crohn ' s disease 





Cardiovascular disease ; angioplasty 




IV . Antibodies V . Examples 
Certain aspects of the embodiments provide antibodies The following examples are included to demonstrate that comprise the chimeric polypeptides of the embodi 
ments . Thus such antibodies can engage the effector func preferred embodiments of the invention . It should be appre 
tions of Fca and Fcy receptors . Such antibodies can be ciated by those of skill in the art that the techniques 
produced recombinantly , for example , by fusing chimeric 40 chimeric 40 disclosed in the examples which follow represent techniques 
polypeptides of the embodiments with an appropriate VH discovered by the inventor to function well in the practice of 
domain and expressing it with an appropriate Ig light chain . the invention , and thus can be considered to constitute 
For example , an antibody of the embodiments can comprise preferred modes for its practice . However , those of skill in preferred modes for its practice . However , those of skill in 
a chimeric polypeptide of the embodiments and the CDRs of the art should , in light of the present disclosure , appreciate 
a known therapeutic antibody such as one of those in Table 45 that many changes can be made in the specific embodiments 
A below . which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention . 
TABLE A Example 1 – Design of the IgG - IgA Chimeras 
Therapeutic antibodies : 
In order to recapitulate binding affinity for FcaRI in an 
Antibody Indication IgGl scaffold , several domain swap variants were con 
Cancer structed by replacement of residues in the IgG1 CH2 and 
CH3 domains with the corresponding IgAl sequences . 
Alemtuzumab B - CLL , CTCL , T - cell lymphoma Mutant B replaces IgG1 residues 336 - 443 ( KGQPR . . . 
Bevacizumab Certain metastatis cancers ( colon , lung , renal , LSPGK , Kabat numbering ; SEQ ID NO : 10 ) with IgA1 glioblastoma ) 
Brentuximab Anaplastic large cell lymphoma ( ALCL ) , Hodgkin residues 335 - 444 ( SGNTF . . . KTIDR ; SEQ ID NO : 9 ) . This 
vedotin lymphoma mutant was generated as a negative control for ELISA 
Catumaxomab Malignant ascites assays and has previously been shown not to have affinity for 
Cetuximab Colorectal cancer , Head and neck cancer 60 the FcaRI receptor ( Pleass et al . , 1999 ) . Mutant C replaces Clivatruzumab Pancreatic cancer 
tetraxetan IgG1 residues 336 - 443 ( KGQPR . . . LSPGK ; SEQ ID NO : 
Denosumab Postmenopausal osteoporosis , Solid tumor bony 10 ) and 242 - 254 ( PKPKDTLMISRTPE ; SEO ID NO : 16 ) 
metasteses with IgA1 residues 336 - 443 ( SGNTF . . . KTIDR ; SEQ ID 
Gemtuzumab Acute myelogenous leukemia NO : 9 ) and 245 - 257 ( PALEDLLLGSEAN ; SEQ ID NO : ozogamicin 
Ibritumomab B cell non - Hodgkin ' s lymphoma 65 14 ) , respectively . In the IgA : FcaRI crystal structure the al 
tiuxetan IgA CH2 domain loop ( PALEDLLLGSEAN ; SEQ ID NO : 
14 ) makes extensive contacts with the FcaRI receptor ( Herr 
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et al . , 2003 ) . The entire al loop ( PALEDLLLGSEAN ; SEQ ELISA Testing 
ID NO : 66 ) from IgA was substituted into IgG in order to ELISA plates ( Qiagen ) were coated with 4 ug / mL of each 
preserve native contacts . Mutant D replaces IgG1 residues of the mutant Fc domains in 1xPBS ( pH 7 . 4 ) overnight at 4° 
336 - 443 ( KGOPR . LSPGK : SEO ID NO : 10 ) and C . The next day the plates were blocked for 2 hours at room 
242 - 254 ( PKPKDTLMISRTPE ; SEQ ID NO : 16 ) with IgA1 5 M 5 temperature with 2 % milk in 1xPBS containing 0 . 05 % 
residues 336 - 443 ( SGNTF . . . KTIDR ; SEQ ID NO : 9 ) and Tween ( PBST ) and washed three times in PBST at pH 7 . 4 . To the first well , 66 uL of 20 ug / mL of either FcyRI - GST , 245 - 257 ( PALEDLLLGSEAN ; SEQ ID NO : 14 ) , respec FcyRI - GST , FcyRIIa - R131 - GST , FcyRIIb - GST , or 
tively , but contains an additional glycine following IgA1 FcyRIIIa - F158 - GST dissolved in PBS with 2 % milk 
residue 257 ( FIG . 1A ) . The glycine residue was added to ( PBSM ) was added followed by 1 : 4 serial dilution . After 1 
ensure that the length of the modified IgG CH2 polypeptide hof incubation at room temperature , the plates were washed 
is consistent with that of the authentic IgG , thus preserving and 50 UL PBSM was added containing 1 : 5000 goat anti 
secondary structure contacts . GST HRP ( GE Healthcare ) for 1 hour . To develop the plates , 
the wells were washed 3x with PBST , 50 uL TMB substrate 
Example 2 – Construction and Expression of Fc was added per well ( Thermo Scientific ) , 50 uL of 1 M 
Domain IgA / G Chimeras 15 H , SO , was added to neutralize , and the absorbance at 450 nm was recorded . Mutant D was shown to have binding for 
both FcaRI ( FIG . 3 ) and the Fey class of receptors ( FIGS . All plasmids and primers are described in Tables 1 and 2 . 4 - 6 ) . FcaRI binding was shown to be reduced compared to DNA sequences for mutants B - D were assembled by PCR wild - type glycosylated IgA , whereas affinity for FcyRI was 
using oligonucleotide primers synthesized in house shown 20 largely retained . Mutant D has reduced affinity to FcyRIIb 
in Table 2 ( Mutant B — WK188 , 190 , 194 , 196 , 198 , 200 , but only marginally reduced affinity to FeyRila . 
202 , 204 , 206 , 207 ; Mutant C — WK188 , 191 , 194 , 196 , 198 , 
200 , 202 , 204 , 206 , 207 ; Mutant D WK188 , 192 , 194 , 196 , Example 4 - Alanine Mutagenesis 
198 , 200 , 202 , 204 , 206 , 207 ) . Each of the IgG mutants were 
then cloned into pMaz - FcyRI - His by Overlap Extension 25 en cloned into Maz - FCYRI - His hy Overlan Extension 25 Alanine scanning mutagenesis on IgA was performed to 
PCR . Double stranded megaprimers for mutant B ( pMaz help identify residues important for binding to FcaRI . Based on crystal structure and Rosetta modeling , 11 sites in the IgA IgH MutB ) were generated with primers WK366 and Fc domain were selected for alanine scanning mutagenesis WK209 and for both mutants C ( PMaz - IgH MutC ) and D ( FIG . 1B ; FIG . 7 ) . The following IgA mutants containing ( pMaz - IgH MutD ) using primers WK370 and WK209 . L257A ( constructed using primers TKA4 , TKA5 ) , L258A Following Dpnl digestion and transformation into JUDE - 1 30 ( constructed using primers TKA6 , TKA7 ) , E313A ( con cells , plasmid DNA was prepared ( Qiagen , HiSpeed Plasmid structed using primers TKA8 , TKA9 ) , N316A ( constructed 
Midi Kit ) for transfection . 293Fectin Transfection Reagent using primers TKB1 . TKB2 ) , H317A ( constructed using 
( Invitrogen ) was used to transfect HEK293F ( Invitrogen ) primers TKB3 , TKB4 ) , R382A ( constructed using primers 
cells cultured in GIBCO FreeStyleTM 293 Expression TKB7 , TKB8 ) , E389A ( constructed using primers TKC1 , 
Medium ( Invitrogen ) in accordance with the manufacturer ' s 35 TKC2 ) , M433A ( constructed using primers TKC5 , TKC6 ) , 
instructions . Five to six days after transfection , the cell E437A ( constructed using primers TKD1 , TKD2 ) , L441A 
suspension was centrifuged at 2 , 000 rpm for 10 min to ( constructed using primers TKD5 , TKD6 ) , and F443A ( con 
recover the supernatant fraction . PBS ( 25x ) was added to a structed using primers TKE1 , TKE2 ) were generated using 
final concentration of 1x in addition to 10 mM imidazole , Quickchange PCR with pTrc - DsbA IgA CH2 CH3 as the 
and the solution was passed through Ni - NTA affinity col - 40 DNA template . Cloning into the mammalian expression 
umns for IMAC chromatographic isolation of the Fc pro - vector pMaz - IgH was achieved by Gibson assembly ( Gibson 
teins . Bound protein was washed with PBS containing 20 et al . , 2009 ) after amplification of the individual Fc domains ( Primers WK346 and WK347 ) and amplification of the mM imidazole and eluted in PBS with 250 mM imidazole pMaz - IgH - FcYRI - His backbone ( Primers WK212 and directly into Amicon 10 kDa spin columns for buffer 
exchange and concentration . SDS - PAGE analysis showed 45 WK314 ) . Following transformation into E . coli JUDE - 1 cells , the mutant genes were sequenced and DNA was good assembly for mutant D but not for mutants B and C prepared for transient transfection in HEK293F cells ( Invit indicating the addition of the glycine to the CH2 loop in the rogen ) . IgA was purified as in Example 2 above . ELISA IgG structure is likely required for good assembly ( FIG . 2 ) . analysis was used to evaluate binding to FcaRI . Briefly , 
each IgA variant was coated at 4 ug / mL onto ELISA plates Example 3 — Binding Properties to FcyRs 50 ( Qiagen ) , then FcaRI - GST at 10 ug / mL was added to the 
first well and serially diluted before detection with goat Mammalian Expression of Fc Receptors . anti - GST HRP as described in Example 2 . Alanine substi 
FcaRI - GST , FcyRI - GST , FcyRIIa - R131 - GST , FcyRIIb tutions at positions 258 , 313 , 316 , and 433 resulted in very 
GST , and FcyRIIIa - F158 - GST were produced by transient significant decrease in binding activity ( FIG . 8 ) . Moderate 
transfection of HEK293F cells ( Invitrogen ) using the 55 reductions in affinity occurred when mutations were made at 
PMAZ - IgH ( U . S . Pat . No . 8 , 043 , 621 , incorporated herein by positions 382 , 389 , and 443 , while little effect on binding 
reference ) derived expression vectors described in Table 1 . was observed at positions 257 , 317 , 437 and 441 . Residues 
Glutathione Sepharose ( GE Healthcare ) affinity chromatog that have a relatively modest effect on binding to the 
raphy was used according to the manufacturer ' s instructions receptor may be optimized by mutagenesis and screening to 
to purify each variant to > 95 % purity as assessed by SDS - 60 impart higher binding affinity for the IgG / A chimera , mutant 
PAGE . PBS at 25x concentration was added to the filtered D , onto FcaRi . 
supernatants six days after transfection to make a final PBS 
concentration of 1x , and the mixture was passed twice over Example 5 / Construction and Expression of Full 
the column . The column was washed with 100 mL of 1xPBS Length IgA / G Chimeras and Control Antibodies 
to remove nonspecifically bound protein . Four milliliters of 65 
1xPBS containing 10 mM reduced glutathione was used for All plasmids and primers are described in Tables 1 and 2 . 
elution into 10 kDa filter columns . Plasmids for expression of wild type trastuzumab IgG heavy 
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chain ( pMaz - IgH - trastuzumab ) , trastuzumab kappa light zumab MutD by amine coupling at pH 5 . 0 . Concentrations 
chain ( pMaz - IgL - trastuzumab ) and trastuzumab IgG N297D ranging from 400 nM to 0 nM of soluble FcyRI ( R & D 
heavy chain ( pMaz - IgH - N297D - trastuzumab ) were con systems ) were flowed in duplicate across the chip at 20 
structed as described previously ( Jung et al . 2012 ) . Inserts ul / min . The resulting binding profiles were fit to a 1 : 1 
for trastuzumab IgA heavy chain ( Primers WK353 and 5 Langmuir isotherm model with local Rmax using Biaevalu 
WK354 ) and trastuzumab MutD heavy chain ( Primers ation 3 . 0 software . The chip was regenerated after each 
WK364 and WK 356 ) were amplified for cloning into the binding event with 100 mM Sodium Citrate pH 3 . 0 with a 
pMaz - IgH ( U . S . Pat . No . 8 , 043 , 621 ) expression plasmid by contact time of 30 seconds . MutD retains close to wild type 
OLE PCR . In each case plasmid pMaz - IgH - trastuzumab was affinity ( 6 nM ) for FcyRI when compared to values previ 
used as the DNA template . After transformation into E . coli 10 ously reported , as seen in FIG . 10 ( Jung et al . 2010 ) . 
JUDE - 1 cells , colonies were isolated for sequencing and For evaluation of FcaRI binding to trastuzumab MutD 
DNA was prepared for each heavy chain and combined with and trastuzumab IgA , CM5 chips were immobilized with 
an equal mass of light chain plasmid for transient transfec each of the antibodies by amine coupling . Concentrations 
tion in HEK293F cells ( Invitrogen ) . Five to six days after ranging from 300 nM to 0 nM of soluble dimeric FcaRI 
transfection , the cell suspension was centrifuged at 2000 15 GST were flowed in duplicate across the chip at 30 ul / min . 
rpm for 10 min to recover the supernatant fraction . Trastu - A three step regeneration was used after each binding event ; 
zumab IgG and trastuzumab IgG N297D were purified over 2 minutes of 50 mM glycine buffer pH 4 . 0 , 2 minutes of 50 
protein A affinity columns whereas trastuzumab IgA and mM glycine pH 9 . 5 and 2 minute of 3 M NaCl . Because of 
trastuzumab Muts were purified over protein L affinity the dimeric nature of the receptor , the data was fit using a 2 : 1 
columns . Briefly , the supernatants were passed through 0 . 22 20 bivalent analyte model with Biaevaluation 3 . 0 software . 
um filters before addition to polypropylene columns packed Trastuzumab MutD , as shown in the sensorgram in FIG . 11 , 
with either Protein A high capacity agarose resin ( Thermo displays significant binding for FcaRI ( 1000 nM ) within the 
Scientific ) or Protein L agarose resin ( Invivogen ) . The range of what was detected for trastuzumab IgA ( 500 nM ) 
resulting flow - through was collected and passed twice more shown in FIG . 12 . 
through the column before any unbound protein was washed 25 For affinity determination of FcyRlla and FcyRIIa - R131 
away with > 10 CV ( Column Volume ) of 1xPBS . All anti - binding to trastuzumab MutD and trastuzumab IgG , anti 
bodies were eluted with 3 ml of 100 mM citrate buffer ( pH bodies were immobilized by amine coupling to CM5 chips 
3 . 0 ) and immediately neutralized with 1 ml of 1 M Tris ( pH at pH 5 . 0 in 50 mM Sodium Acetate buffer . Concentrations 
8 . 0 ) . Samples were buffer - exchanged into 1xPBS using ranging from 10 uM to 0 uM of monomeric FcyRIIb and 
Amicon Ultra - 4 ( Millipore ) spin columns with a 10 kDa 30 FcyRIIa - R131 were flowed in duplicate across the chip at 20 
cutoff and the purity of purified samples was assessed by ul / min until an equilibrium state was achieved . Dissociation 
4 - 20 % gradient SDS - PAGE gel ( NuSep ) . SDS - PAGE analy . was performed using an 8 minute step in the HBS - EP 
sis revealed better assembly of MutD than IgA as seen in running buffer ( GE Healthcare ) . A 1 : 1 Langmuir isotherm 
FIG . 9 . model was fit to the equilibrium data to obtain K , values for 
35 each of the interactions . As indicated in FIG . 13 FcyRIIb 
Example 6 — Binding Properties of Full Length displays and affinity of 4 . 33 uM for MutD and a higher 2 . 55 
Antibodies to FcyRs uM affinity for IgG , presented in FIG . 14 . MutD also retains 
an affinity of 2 . 02 uM for the low affinity R131 allele of 
Mammalian Expression of Monomeric FcyRIIa and FeyRIIa as seen in FIG . 15 in comparison to 1 . 14 um for 
FcyRIIb Receptors . 40 binding of this receptor to IgG as seen in FIG . 16 . 
The genes encoding monomeric low affinity Fc receptors 
( FcyRIIa and FcyRIIb ) were generated by Gibson assembly Example 7 – Antibody Dependent Cell Cytotoxicity 
as follows : The backbone of the pcDNA3 . 4 vector ( Invit Assays for the Killing of Cancer Cells by the 
rogen ) was amplified in two segments ; a 2 . 5 kb fragment Engineered Antibodies and Using Neutrophils as 
( using primers WK426 and WK463 ) and a 3 . 5 kb fragment 45 the Effector Cells 
( using primers WK425 and WK464 ) . The insert for FcyRIIa 
R131 was created using primers WK448 and WK461 with ADCC Assays . 
plasmid pMaz - IgH - FcyRIIaR131 - His ( Jung et al . 2012 ) as a Human neutrophils were isolated from Heparin - treated 
template . Similarly the insert for FcyRIIb was generated fresh human blood gathered from anonymous donors ( IRB 
using primers WK450 and WK462 with pMaz - IgH - 50 protocol 2012 - 08 - 0031 ) on the day prior to the ADCC assay . 
FcyRIIb - GST ( Jung et al . 2012 ) as a template . Each insert 10 ml of blood was diluted 1 : 1 with PBS ( Mediatech ) and 
was combined with the two backbone segments for 60 layered over 13 ml of room temperature Histopaque 1077 
minutes at 50° C . in a Gibson master mix ( Gibson et al . ( Invitrogen ) in 50 ml conical tubes . The mixture was cen 
2009 ) , to create the plasmids pcDNA3 . 4 - FcyRIIb - His and trifuged at 2500 rpm for 30 minutes at 25° C . with no brake 
pcDNA3 . 4 - FcyRIIaR131 - His , before transformation into E . 55 during the deceleration phase . Serum , Histopaque and 
coli . The respective plasmids for FcyRIIa - R131 and FcyRIIb mononuclear cells were discarded . The pellet was resus 
expression were transfected for 5 - 6 days using Expi293F pended in 4° C . cold shock buffer ( 155 mM Ammonium 
cells ( Invitrogen ) . Purification was performed by Ni - NTA Chloride , 10 mM Potassium Bicarbonate and 0 . 1 mm 
affinity chromatography as described previously and expres EDTA ) and incubated on ice for 10 minutes to lyse the red 
sion confirmed by 4 - 20 % SDS page gel . 60 blood cells . The neutrophil fraction was isolated by centri 
SPR Affinity Measurements . fuging at 1300 rpm for 7 minutes and washing twice with 50 
A Biacore 3000 instrument ( GE Healthcare ) was used to ml PBS . After the final wash , the neutrophils were resus 
determine K , values for MutD binding to FcyRI , FcyRIIa pended in RPMI media containing 10 % FBS as well as 50 
R131 , FcyRIIb and FcaRI . In all cases amine coupled BSA ng / ml IFN - Y ( Peprotech ) . The cells were cultured overnight 
reference channels were used to subtract nonspecific binding 65 at a concentration of 5x100 cells / ml in a 24 well plate under 
signal . To determine MutD affinity for FcyRI , CM5 chips a humidified atmosphere of 5 % CO2 . The following day 
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confirm activation . Meanwhile , SKBR - 3 tumor cells ( ATCC ) each pH as shown in FIG . 19 . The increased affinity over 
were cultured in McCoy ' s 5a media containing 10 % FBS wild type IgG is likely caused by the improved avidity of 
( Invitrogen ) and Penicillin - Streptomycin ( Invitrogen ) . On this construct . 
the day of the assay the tumor cells were recovered by 
trypsinization and labeled for 90 minutes with Cr51 ( Perkin 5 TABLE 1 
Elmer ) in a 1 ml volume at a density of 1x10 cells / ml . The 
Primers used in this study tumor cells were washed 3 times in RPMI containing 10 % ( provided as SEO ID NOS : 17 - 53 ) 
FBS and seeded in 96 well v bottom plates at 5000 cells / 
well . Antibody variants at various concentrations were Primer 
70 10 Name Primer nucleotide sequence ( 5 ! ? 3 ' ) added to opsonize the tumor cells for 30 mins at 37° C . 
Neutrophils were then added at a 1 : 80 tumor : effector cell JL - Gibson F TGAGCGGCCGCTCGAGGC ( SEQ ID NO : 40 ) 
ratio and the plates incubated at 37° C . with 5 % CO , for 4 IL - Gibson TTTGCCCGCCAGCCTGTCGATGGTCTTCTGGGTGAA hours . Supernatants were recovered and 50 ul was added to ( SEQ ID NO : 41 ) 
Uncoated Scintiplate - 96 plates ( PerkinElmer ) . After over - 16 
night drying the plates were read in a MicroBeta scintillation L - GS - C CGACAGGCTGGCGGGCAAAGGCGGCGGCGGCAGCCA GAG counter ( PerkinElmer ) . The ADCC assays presented in FIG . Rn - 1 ???cTGCAccGccC????cGGcG 
17 show trastuzumab MutD is able to activate neutrophils to ( SEO ID NO : 42 ) 
kill SkBR3 breast cancer tumor cells . In contrast , clinical JL - GS - C GCCTCGAGCGGCCGCTCAGCCGTTGCAGGGGTGCAG grade trastuzumab cannot mediate killing of SKBR - 3 cells 20 GCC 
with neutrophils as effectors . Trastuzumab MutD displayed Rn - 2 GCCGAAGTGGCCGGTGCA ( SEQ ID NO : 48 ) 
a killing efficiency towards SkBr3 breast cancer cells similar L - GS - L CGACAGGCTGGCGGGCAAAGGCGGCGGCGGCAGCCA to that of trastuzumab IgA comprising the Fab domain of GAG 
trastuzumab fused to an IgA Fc domain . Unlike trastuzumab Rn - 1 ATTCGTGACCGGCCACTTCGGCG ( SEQ ID NO : 49 ) MutD which binds to Fcy receptors as described in Example 25 
6 , trastuzumab IgA shows no binding to the Foy receptors . JL - GS - L GCCTCGAGCGGCCGCTCAGCCGTTGGCGGGGTACAG 
GCC 
Example 8 Conjugation of MutD with a FcRn Rn - 2 GCCGAAGTGGCCGGTCAC ( SEQ ID NO : 51 ) 
Binding Peptide GCGTTGGAAGACCTTGCGCTTGGTAGCGAAGCG 
30 ( SEQ ID NO : 17 ) 
Mammalian expression of FcRn peptide fusion to MutD : 
cGc??cGC?AccAAGCGCAAGGTc??ccAACGC In order to reintroduce FcRn Binding to the Mutt frame ( SEQ ID NO : 18 ) 
work a C - terminal fusions with either a linear ( QRFVTGH 
FGGLYPANG ; SEQ ID NO : 67 ) or a cyclic binding peptide TKA6 CGTTGGAAGACCTTCTGGCGGGTAGCGAAGCGAATCTG 
( QRFCTGHFGGLHPCNG ; SEQ ID NO : 68 ) were gener - 35 ( SEQ ID NO : 19 ) 
ated by Gibson assembly ( Sockolosky et al . 2012 ) . The CAGATTCGCTTCGCTACCCGCCAGAAGGTCTTCCAACG 
linear peptide insert was created using primers JL - GS - L - Rn ( SEQ ID NO : 20 ) 
1 and JL - GS - L - Rn 2 and the cyclic peptide insert was 
generated with JL - GS - C - Rn 1 and JL - GS - L - Rn 2 primers . CTGTCGGGTTGCGCAcccccGTGGAATCATGGC 
( SEO ID NO : 21 ) The vector backbone was created by amplifying a 6 . 5 kb 40 
fragment from pcDNA3 . 4 - IgH - Trastuzumab - MutD using GCCATGATTCCACGGCGCTGCGCAACCCGACAG 
primers JL - Gibson R and JL - Gibson F . Following transfor ( SEQ ID NO : 22 ) 
mation into E . coli and sequencing to verify cloning success 
GGTTGCGCAGAACCGTGGGCGCATGGCAAAACATTCAC the linear and cyclic variants were transfected into Expi293 ( SEQ ID NO : 23 ) 
cells as above . After 5 days of culture the proteins were 45 
isolated by Protein L chromatography as described in TKB2 GTGAATGTTTTGCCATGCGCCCACGGTTCTGCGCAACC 
Example 5 and eluted in 100 mM PH 2 . 7 glycine HC1 . ( SEQ ID NO : 24 ) 
ELISA Assay : GCGCAGAACCGTGGAATGCGGGCAAAACATTCACCTG ELISA plates were coated with 4 ug / ml FcRn in PBS ( SEQ ID NO : 25 ) 
overnight . The following day wells were blocked with PBST 50 
containing a 2 % milk solution for 2 hours at room tempera CAGGTGAATGTTTTGC?CGCATTccACGGTecTGCGC 
( SEQ ID NO : 26 ) ture and washed 3x with PBST at pH 7 . 4 . To the first well 
antibody variant was added at 140 ug / ml in either pH 7 . 4 TKB7 CGAAAGATGTTCTGGTGGCGTGGCTGCAGGGAAGCC 
PBS or pH 5 . 8 PBS with 40 mM MES and serially diluted ( SEQ ID NO : 27 ) 
by a factor of 4 . After 1 hour at room temperature the plates 55 
TKB8 GGC??cccTGCAGCCAccccAccAGAAC?T????cG were washed 3x with either pH 7 . 4 PBS or pH 5 . 8 PBS with ( SEQ ID NO : 28 ) 40 mM MES respectively depending on the pH at which the 
antibody was bound . The presence of antibody was detected TKC1 TGCAGGGAAGCCAAGCGCTGCCCCGTGAAAAG 
by 1 hour incubation with a 1 : 5000 dilution of goat anti ( SEQ ID NO : 29 ) 
human CK HRP in PBST with 2 % milk , washing with pH 7 . 4 60 TKO ?????cAcGGGGCAGCGCTIGGC??cccTGCA PBS or pH 5 . 8 PBS with 40 mM MES buffer and develop ( SEQ ID NO : 30 ) 
ment with 50 ul TMB substrate . The reaction as quenched 
with 50 ul 1M H , SO , was added to neutralize , and the TKC5 GATACGTTCAGCTGCGCGGTGGGCCATGAGGC 
absorbance at 450 nm was recorded . The cyclic peptide ( SEQ ID NO : 31 ) 
exhibited the highest binding to FcRn at both pH 5 . 8 and pH 65 TKC6 GCCTCATGGCCCACCGCGCAGCTGAACGTATC 
7 . 4 with higher binding observed at the lower pH . The linear ( SEQ ID NO : 32 ) 
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TABLE 1 - continued TABLE 1 - continued 
Primers used in this study 
( provided as SEO ID NOs : 17 - 53 ) 
Primers used in this study 
( provided as SEO ID NOS : 17 - 53 ) 
5 Primer 
Name Primer Primer nucleotide sequence ( 5 ' ? 3 ' ) 
Name Primer nucleotide sequence ( 5 ' ? 3 ' ) 
TKD1 ATGGTGGGCCATGCGGCAc??ccGCTG 




CAC ( SEQ ID NO : 74 ) TKD2 CAGCGGAAGTGCCGCATGGCCCACCAT ( SEQ ID NO : 34 ) 
TKD5 WK463 GCCATGAGGCACTTCCGGCGGCCTTTACTCAAAAAAC 
( SEQ ID NO : 35 ) 
CGCCTTATCCGGTAACTATCGTCTTG 
( SEQ ID NO : 75 ) 
15 
TKD6 WK464 GTTTTTTGAGTAAAGGCCGCCGGAAGTGCCTCATGGC 
( SEQ ID NO : 36 ) 
GACTCAAGACGATAGTTACCGGATAA 
( SEQ ID NO : 76 ) 
TKE1 GAGGCACTIccGCTGGccGcGACTCAAAAAACTATT - 
GAT 
C ( SEQ ID NO : 37 ) 20 20 TABLE 2 
TKE2 GATCAATAGTTTTTTGAGTCGCGGCCAGCGGAAGT 
Gcc? 
C ( SEQ ID NO : 38 ) 
Oligonucleotides used for gene assembly in 
this study ( SEO ID NOs : 54 - 65 ) 
WK209 CGAGGCTGATCAGCGAGCT ( SEQ ID NO : 39 ) Primer 
25 Name Oligonucleotide sequence ( 5 ! ? 3 ' ) 
WK314 TGATCTAGAAGCTCGCTGATCAGCCTC 








CCCC ( SEQ ID NO : 44 ) 30 
WK190 
WK347 CGAcccTGATCAGCGAcc??c?????cAGTGATGGT - 
GAT 






WK353 35 GGACAATGGTCACCGTCTCCTCAGCGAGC 
CCGACGTCTC 





GACTGACGGTCCC WK354 GGCTGATCAGCGAGCTTCTAGATCATTTGCCCGCCA 
GAC 
GATCAATAGTTTTTTGAGTAAAGGCCAGCGG 










GGTGGA ( SEQ ID NO : 50 ) 


















WK425 TGAGCGGCCGCTCGAG ( SEQ ID NO : 69 ) WK198 
55 WK426 ACACTGGACACCTTTGAGCACAGC 















ATGCACCTCGGGTCTGAAG WK450 CGCTGTGCTCAAAGGTGTCCAGTGTACACCTGCA 
GCTCC 
CCCAAAGG ( SEQ ID NO : 72 ) WK202 
WK461 GTGGTGATGGTGATGATGCCCCATTGGTGAAGAGCT - 
GCC 
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TABLE 2 - continued Example 9 Screening for Higher Affinity 
Oligonucleotides used for gene assembly in 
this study ( SEQ ID NOS : 54 - 65 ) 
Primer 
Name oligonucleotide sequence ( 5 ! ? 3 ' ) 













Plasmids used in this study 
Reference or 
Source Plasmids Relevant characteristics 
Structure - Based Library Design . 
At Fc residues found to have the modest influence on 
5 interaction with FcaRI and at residues in close proximity to 
energetically important residues , mutations can be intro 
duced to create combinatorial libraries of mutant D likely to 
give rise to variants displaying higher affinity to FcaRi . 
Biased codons can be chosen where possible to reduce the 
10 size of the library required to cover the total theoretical 
diversity . Gene assembly is used to generate a library based 
on mutant D with a theoretical diversity of about 1x108 . 
Primers specific for the library can be used for amplification 
and cloning into Sfil - digested pPelBFLAG . The resulting 
15 plasmid library was transformed into E . coli Jude - 1 ( F ' 
[ Tn10 ( Tetr ) proAB + laciq A?lacZ ) M15 ] mcr , A ( mrr - hs 
dRMS - mcrBC ) 980dlac ZAM15 AlacX74 deoR recA1 
araD139 A?ara leu ) 7697 galu galK rpsL endAl nupG ) and 
plated on LB agar plates containing chloramphenicol and 
20 2 % glucose ( w / v ) . 
Error Prone Library Construction . 
In addition to the library design guided by alanine scan 
ning mutagenesis , the mutant D gene can be randomly 
mutated by error prone PCR since there are established 
25 instances where mutations located distal to a receptor bind 
ing site can have a large influence on the affinity of the 
interaction ( Jung et al . , 2010 ; Jung et al . , 2012 ) . Using a 
standard error prone PCR method ( Fromant et al . , 1995 ) and 
mutant D as a template , a library insert can be generated . The 
30 amplified fragment can be Sfil digested and ligated into 
pPelBFLAG digested in the same manner . The resulting 
plasmids are then transformed into JUDE - 1 cells by elec 
troporation and plated on LB agar plates containing 
chloramphenicol and 2 % glucose ( w / v ) . An error prone 
35 library exceeding 1x108 individual variants can be created 
with an error rate of 0 . 6 % as calculated from the sequencing 
of 10 randomly chosen variants . 
Library Screening Spheroplast Preparation . 
Thawed aliquots of library cells can be cultured for six 
40 hours at 37° C . with 250 rpm shaking in Terrific Broth 
( Becton Dickinson ) with 2 % ( w / v ) glucose supplemented 
with chloramphenicol ( 50 ug / mL ) then diluted 1 : 50 in fresh 
TB media containing 0 . 5 M trehalose ( Fisher Scientific ) and 
chloramphenicol ( 40 ug / mL ) . After three hours incubation at 
45 37° C . with 250 rpm shaking and a 20 min cooling step at 
25° C . , the expression of Fc fragments is induced with 1 mM 
isopropyl - 1 - thio - ß - D - galactopyranoside ( IPTG ) . After cul 
ture overnight at 25° C . , 8 OD equivalents of the culture 
broth can be harvested by centrifugation and washed two 
50 times in 1 mL of cold 10 mM Tris - HCl ( pH 8 . 0 ) . After 
resuspension in 1 mL of cold STE solution ( 0 . 5 M Sucrose , 
10 mM Tris - HC1 , 10 mM EDTA , pH 8 . 0 ) , the cells are 
incubated with rotating mixing at 37° C . for 30 min , 
recovered by centrifugation at 12 , 000xg for 1 , and washed 
55 in 1 mL of cold Solution A ( 0 . 5 M sucrose , 20 mM MgCl2 , 
10 mM MOPS , pH 6 . 8 ) . The washed cells are incubated in 
1 mL of Solution A containing 1 mg / mL of hen egg 
lysozyme at 37° C . for 15 min . After centrifugation at 
12 , 000xg for 1 min the resulting spheroplasts pellets were 
60 resuspended in 1 mL of cold PBS . 
Library Screening Cell Sorting . 
For library screening , the extracellular domain of recom 
binant expressed FcaRI - GST / CD89 can be fluorescently 
labeled with an Alexa Fluor 488 labeling kit ( Invitrogen , 
65 Carlsbad , Calif . ) . After the labeling reaction , the activity of 
FcaRi - GST was confirmed using ELISA by determining 
receptor association with coated human IgA from serum 
pTre - DsbA IgA CH2 IgA Fc domain with truncated This study 
CH3 tailpiece ( Residues 222 - 445 ) in 
bacterial expression vector 
pMaz - IgH - FcaRI - GST FcaRI gene in pMaz - IgH for This study 
dimeric 
mammalian expression 
pMaz - IgH - FcyRI - His FcyRI gene in pMaz - IgH for This study 
monomeric mammalian expression 
pMaz - IgH - FcYRI -GST FcyRI gene in pMaz - IgH for ( Jung et al . , 
dimeric 
mammalian expression 
pMaz - IgH - FcyRIIaR131 - FcyRIIa gene in pMaz - IgH for ( Jung et al . , 
GST dimeric mammalian expression 2012 ) 
pMaz - IgH - FcyRIID FcyRIIb gene in pMaz - IgH for ( Jung et al . , 
GST dimeric mammalian expression 2012 ) 
pMaz - IgH - FcyRIIIa FcyRIIIa gene in pMaz - IgH for ( Jung et al . , 
GST dimeric mammalian expression 2012 ) 
pMaz - IgH - MutB Mutant B Fc domain only in This study 
dimeric 
mammalian expression vector 
pMaz - IgH - MutC Mutant C Fc domain only in This study 
dimeric 
mammalian expression vector 
pMaz - IgH - MutD Mutant D Fc domain only in This study 
dimeric 
mammalian expression vector 
pMaz - IgH - trastuzumab Wild type IgG1 trastuzumab heavy ( Jung et al . , 
chain mammalian expression vector 2012 ) 
pMaz - IgL - trastuzumab Wild type IgG1 trastuzumab kappa ( Jung et al . , 
light chain mammalian expression 2012 ) 
vector 
pMaz - IgH - IgA Wild type IgAl trastuzumab This study 
trastuzumab mammalian expression vector 
pMaz - IgH - N297D IgG1 trastuzumab heavy chain ( Jung et al . , 
trastuzumab mammalian expression vector with 2012 ) 
glycosylation knockout at N297 
pMaz - IgH - MutD Mutant D trastuzumab in a This study 
trastuzumab mammalian expression vector 
pcDNA3 . 4 - FcyRIIb Soluble His tagged monomeric This study 
His FcyRIIb mammalian expression 
vector 
pcDNA3 . 4 Soluble His tagged monomeric This study 
FeyRIIaR131 - His FcyRIIaR131 mammalian expression 
vector 
2012 ) 
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28 
using goat anti - GST HRP for detection . Spheroplasts are Woof , J . , and Kerr , M . ( 2004 ) IgA function — variations on 
labeled with 100 nM of FcaRI - GST - 488 in PBS at 4° C . for a theme , Immunology 113 , 175 . 
1 hour . During the 4th round of sorting , the concentration of van Egmond , M . , Damen , C . , van Spriel , A . , Vidarsson , G . , 
FcaRI - GST was reduced to 50 nM and finally to 20 nM in van Garderen , E . , and van de Winkel , J . ( 2001 ) IgA and 
the final round . More than 4x108 spheroplasted cells can be 5 the IgA Fc receptor , TRENDS in Immunology 22 , 205 
sorted on an Aria flow cytometer ( BD Biosciences ) equipped 211 . 
with a 488 nm laser for excitation . In each round the top 3 % Stockmeyer , B . , Dechant , M . , van Egmond , M . , Tutt , A . , of the population showing the highest fluorescence due to Sundarapandiyan , K . , Graziano , R . , Repp , R . , Kalden , J . , Fcarla - GST - 488 binding can be isolated and resorted Gramatzki , M . , and Glennie , M . ( 2000 ) Triggering Fc immediately after the initial sorting . { alpha } - receptor I ( CD89 ) recruits neutrophils as effector Library Screening - Library Recovery . cells for CD20 - directed antibody therapy , The Journal of After each round of sorting the pool of Fc genes in the Immunology 165 , 5954 . spheroplasts can be rescued by PCR amplification using 
specific primers , ligated into pPelBFLAG on Sfil restriction BELAG On Shil restriction Pasquier , B . , Launay , P . , Kanamaru , Y . , Moura , I . , Pfirsch , 
enzyme sites , and transformed back into electrocompetent E . 15 5 S . , Ruffle , C . , Hénin , D . , Benhamou , M . , Pretolani , M . , 
coli Jude - 1 cells . The resulting transformants are plated on and Blank , U . ( 2005 ) Identification of Fc RI as an 
agar plates containing chloramphenicol , recovered , and then Inhibitory Receptor that Controls Inflammation Dual Role 
grown in liquid culture for spheroplasting in subsequent of FcR ITAM , Immunity 22 , 31 - 42 . 
sorting rounds . After five rounds of screening with FcaRI - Pleass , R . J . , Dunlop , J . I . , Anderson , C . M . , and Woof , J . M . 
GST - , a panel of variants with higher fluorescence than 20 ( 1999 ) Identification of Residues in the CH2 / CH3 
mutant D may be isolated . Domain Interface of IgA Essential for Interaction with the 
All of the methods disclosed and claimed herein can be Human Fca Receptor ( FcaR ) CD89 , Journal of Biologi 
made and executed without undue experimentation in light cal Chemistry 274 , 23508 - 23514 . 
of the present disclosure . While the compositions and meth - Herr , A . B . , Ballister , E . R . , and Bjorkman , P . J . ( 2003 ) 
ods of this invention have been described in terms of 25 Insights into IgA - mediated immune responses from the 
preferred embodiments , it will be apparent to those of skill crystal structures of human Fc RI and its complex with 
in the art that variations may be applied to the methods and IgA1 - Fc , Nature 423 , 614 - 620 . 
in the steps or in the sequence of steps of the method Benhar , I . , and Mazor , Y . ( 2008 ) Recombinant fusion protein described herein without departing from the concept , spirit and polynucleotide construct for immunotoxin produc and scope of the invention . More specifically , it will be 30 tion , Google Patents . apparent that certain agents which are both chemically and 
physiologically related may be substituted for the agents Gibson , D . G . , Young , L . , Chuang , R . Y . , Venter , J . C . , 
described herein while the same or similar results would be Hutchison , C . A . , and Smith , H . O . ( 2009 ) Enzymatic 
achieved . All such similar substitutes and modifications assembly of DNA molecules up to several hundred kilo 
apparent to those skilled in the art are deemed to be within 35 bases , Nature methods 6 , 343 - 345 . 
the spirit , scope and concept of the invention as defined by Jung , S . , Reddy , S . , Kang , T . , Borrok , M . , Sandlie , I . , 
the appended claims . Tucker , P . , and Georgiou , G . ( 2010 ) Aglycosylated IgG 
variants expressed in bacteria that selectively bind Fc RI 
REFERENCES potentiate tumor cell killing by monocyte - dendritic cells , 
40 Proceedings of the National Academy of Sciences 107 , 
The following references , to the extent that they provide 604 . 
exemplary procedural or other details supplementary to Jung , S . T . , Kelton , W . , Kang , T . H . , Ng , D . T . W . , Andersen , 
those set forth herein , are specifically incorporated herein by J . T . , Sandlie , I . , Sarkar , C . A . , and Georgiou , G . ( 2012 ) 
reference . Effective Phagocytosis of Low Her2 Tumor Cell Lines 
Woof , J . M . , and Kerr , M . A . ( 2006 ) The function of 45 with Engineered . Aglycosylated IgG Displaying High 
immunoglobulin A in immunity , The Journal of Pathology FcyRIIa Affinity and Selectivity , ACS Chemical Biology . 
208 , 270 - 282 
Morell , A . , Skvaril , F . , Noseda , G . , and Brandun , S . ( 1973 ) Fromant , M . , Blanquet , S . , and Plateau , P . ( 1995 ) Direct random mutagenesis of gene - sized DNA fragments using Metabolic properties of human IgA subclasses , Clinical polymerase chain reaction , Analytical Biochemistry 224 , and Experimental Immunology 13 , 521 . 347 - 353 . Jacob , C . , Pastorino , A . , Fahl , K . , Carneiro - Sampaio , M . , 
and Monteiro , R . ( 2008 ) Autoimmunity in IgA deficiency : Pier , G . B . , Kelly - Quintos , C . A . , Cavacini , L . , and Posner , 
revisiting the role of IgA as a silent housekeeper , Journal M . R . ( 2005 ) Poly - N - acetyl glucosamine ( PNAG / DP 
of Clinical Immunology 28 , 56 - 61 . NAG ) - binding peptides and methods of use thereof , WO 
Oian , K . , Xie , F . , Gibson , A . , Edberg , J . , Kimberly , R . , and 55 Patent W0 / 2005 / 103 , 084 . 
Wu , J . ( 2008 ) Functional expression of IgA receptor Fc Kabat et al . , In : Sequences of Proteins of Immunological 
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SEQUENCE LISTING 
< 160 > NUMBER OF SEQ ID NOS : 82 
V < 210 > SEQ ID NO 1 
< 211 > LENGTH : 227 
< 212 > TYPE : PRT 
V 
V 
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30 
- continued 
< 213 > ORGANISM : Homo sapiens 
< 400 > SEQUENCE : 1 E 
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 
15 
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met &






E E gg Se 3 3 8 4
3 
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
55 
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 
65 70 8 
Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 
95 mam mam & Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 3 & Glu Lys Thr Ile Ser Lys Ala Lys Gly Gin Pro Arg Glu Pro Gin Val 115 120 &mmmmmm ? Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gin Val Ser 135 ? Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 145 150 Trp Glu Ser Asn Gly Gin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 175 ?mmmm Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 4 83 ?Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met 200 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 215 
Pro Gly Lys 
225 
| AAAAA
< 210 > SEQ ID NO 2 
< 211 > LENGTH : 230 
< 212 > TYPE : PRT 
3 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
223 > OTHER INFORMATION : Recombinant Polypeptide 
< 400 > SEQUENCE : 2 
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 
15 





3 RgE & gg2 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 35 40 . ms mmm Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 55 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 70 sm Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 95 
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 
100 105 
US 9 , 890 , 216 B2 
31 
- continued 
? ? ? Glu Lys Thr Ile Ser Lys Ala Lys Ser Gly Asn Thr Phe Arg Pro Glu 
115 120 125 
Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu Leu 
140 
Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys Asp Val Leu 
145 155 160 mmm & ESRVal Arg Trp Leu Gin Gly Ser Gin Glu Leu Pro Arg Glu Lys Tyr Leu 165 175 m? mmm mm Thr Trp Ala Ser Arg Gin Glu Pro Ser Gin Gly Thr Thr Thr Phe Ala 185 190 Val Thr Ser Ile Leu Arg Val Ala Ala Glu Asp Trp Lys Lys Gly Asp 195 200 205 Thr Phe Ser Cys Met Val Gly His Glu Ala Leu Pro Leu Ala Phe Thr 220 
| 
Gin Lys Thr Ile Asp Arg 
225 230 
| AAAAA
< 210 > SED ID No 3 
< 211 > LENGTH : 229 
< 212 > TYPE : PRT 
13 ) ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Recombinant Polypeptide 
< 400 > SEQUENCE : 3 
Asp Lys Thr His Thr Cys Pro Pro cys Pro Ala Pro Glu Leu Leu Gly ? .
Gly Pro Ser Val Phe Leu Phe Pro Pro Ala Leu Glu Asp Leu Leu Leu 
25 So 
Gly Ser Glu Ala Asn Val Thr cys Val Val Val Asp Val Ser His Glu 
35 40 45 
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 
55 3? Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 
Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 
105 
& Lys Thr Ile Ser Lys Ala Lys Ser Gly Asn Thr Phe Arg Pro Glu Val 
115 120 125 
His Leu Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu Leu Val 
135 
ama m? mm smmm mmm mmmmm ? Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys Asp Val Leu Val Arg Trp Leu Gin Gly Ser Gin Glu Leu Pro Arg Glu Lys Tyr Leu Thr ?E HETrp Ala Ser Arg Gin Glu Pro Ser Gin Gly Thr Thr Thr Phe Ala Val 185 ? Thr Ser Ile Leu Arg Val Ala Ala Glu Asp Trp Lys Lys Gly Asp Thr 195 200 205 ? Phe Ser Cys Met Val Gly His Glu Ala Leu Pro Leu Ala Phe Thr Gin 215 | Lys Thr Ile Asp Arg 225 
US 9 , 890 , 216 B2 
33 34 
- continued 
< 210 > SEQ ID NO 4 
< 211 > LENGTH : 230 
< 212 > TYPE : PRT 
ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Recombinant Polypeptide 
V 
< 400 > SEQUENCE : 4 
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly R
& Gly Pro Ser Val Phe Leu Phe Pro Pro Ala Leu Glu Asp Leu Leu Leu 
25 130 
E Gly Ser Glu Ala Asn Gly Val Thr Cys Val Val Val Asp Val Ser His 
40 35 
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr 
70 75 
Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 






sm mmm mmm ? mmGlu Lys Thr Ile Ser Lys Ala Lys Ser Gly Asn Thr Phe Arg Pro Glu 115 120 
gamm 
mmmm mmm Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu Leu smmmmmm Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys Asp Val Leu 150 155 mam Val Arg Trp Leu Gin Gly Ser Gin Glu Leu Pro Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gin Glu Pro Ser Gin Gly Thr Thr Thr Phe Ala 185 190 Val Thr Ser Ile Leu Arq Val Ala Ala Glu Asp ! 195 200 Thr Phe Ser Cys Met Val Gly His Glu Ala Leu Pro Leu Ala Phe Thr Gln Lys Thr Ile Asp Arg 225 230 < 210 > SEQ ID NO 5 
< 211 > LENGTH : 218 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Homo sapiens 
< 400 > SEOUENCE : 5 
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro ?
10 
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 
25 30 
mm e
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
. ?
40 mm Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 55 60 mam ? ? Glu Gin Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 65 70 75 
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- continued 
E His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
85 95 8 
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 
Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu &
Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 
140 
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro Glu Asn 
145 150 155 160 mmm mmm Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 165 175 &PE Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 205 , 
Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 
210 215 
< 210 > SEQ ID NO 6 
< 211 > LENGTH : 221 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Recombinant polypeptide 
< 400 > SEQUENCE : 6 
? Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 
10 15 




Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
45 
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 
50 55 
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 
80 mms mmm His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 95 mmm Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Ser 105 110 gmm mmmmmm mmm mmmm 
5gama mmmm 
mm 
Gly Asn Thr Phe Arq Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu 
125 
&
Glu Leu Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly 
130 135 
Phe Ser Pro Lys Asp Val Leu Val Arg Trp Leu Gin Gly Ser Gin Glu 
145 160 
Leu Pro Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gin Glu Pro Ser 
175 
Gin Gly Thr Thr Thr Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala 
185 190 JR Glu Asp Trp Lys Lys Gly Asp Thr Phe Ser Cys Met Val Gly His Glu 205 Ala Leu Pro Leu Ala Phe Thr Gln Lys Thr Ile Asp Arq 210 215 . ?




1 2 AAAAA 
< 210 > SEQ ID No 7 
< 211 > LENGTH : 220 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Recombinant polypeptide 
2 1 3 
 2 0 
2 2 3 
< 400 > SEQUENCE : 7 
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 





Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu 
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His 
& 
Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys 
85 
gmmm 8?mmm Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Ser Gly &g 1Asn Thr Phe Ara Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu mmmmm mmm mmm ? mm 3sm mem mmm mmm Leu Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys Asp Val Leu Val Arg Trp Leu Gin Gly Ser Gin Glu Leu Pro Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gin Glu Pro Ser Gin Gly Thr Thr Thr Phe Ala Val Thr Ser Ile Leu Ara Val Ala Ala Glu Asp Trp Lys Lys Gly Asp Thr Phe Ser Cys Met Val Gly His Glu Ala Leu Pro Leu Ala Phe Thr Gln Lys Thr Ile Asp Arg 210 215 
AAAAA 
< 210 > SEQ ID NO 8 
< 211 > LENGTH : 221 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Recombinant polypeptide 
< 400 > SEQUENCE : 8 
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro &R ?&
g Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn Gly Val Thr Cys 
25 & g 
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 
35 40 
m
mms as am Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 55 am &RS 1 | mem " &R3 ? & Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 70 His Gin Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 
85 
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- continued 
? ? ° Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Ser 
105 110 |
? &
& Gly Asn Thr Phe Ara Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu 
115 120 




Phe Ser Pro Lys Asp Val Leu Val Arg Trp Leu Gin Gly Ser Gin Glu 
160 
&LE 
SE 3 mmmmm m ? 12Leu Pro Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gin Glu Pro Ser 175 A3D Gin Gly Thr Thr Thr Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala 185 190 
Glu Asp Trp Lys Lys Gly Asp Thr Phe Ser Cys Met Val Gly His Glu 
195 200 
| . 
Ala Leu Pro Leu Ala Phe Thr Gln Lys Thr Ile Asp Arq 
210 215 
?
< 210 > SEQ ID NO 9 
< 211 > LENGTH : 110 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Homo sapiens 
< 400 > SEQUENCE : 9 
Ser Gly Asn Thr Phe Arg Pro Glu Val His Leu Leu Pro Pro Pro Ser ?er Gly Asn Thr phe Arg Pro Glu Val His Leu 
Glu Glu Leu Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arg 
20 
Gly Phe Ser Pro Lys Asp Val Leu Val Arg Trp Leu Gin Gly Ser Gin 




Glu Leu Pro Arq Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gln Glu Pro 
55 
Ser Gin Gly Thr Thr Thr Phe Ala Val Thr Ser Ile Leu Arg Val Ala 
70 80 
Ala Glu Asp Trp Lys Lys Gly Asp Thr Phe Ser Cys Met Val Gly His 
Glu Ala Leu Pro Leu Ala Phe Thr Gln Lys Thr Ile Asp Arg 
100 Glu Ala Leu PES Leu Ala Phe Thr Gap 
< 210 > SEQ ID NO 10 
< 211 > LENGTH : 108 1 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Homo sapiens 
< 400 > SEQUENCE : 10 
Lys Gly Gin Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg ??
. 
Asp Glu Leu Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly 
20 25 
m
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gin Pro &Es
a35 ?g 8 mmmmGlu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 50 55 Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gin Gin 
65 70 & 
Ly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His ?
. 
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Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 
100 105 
AAAA 
< 210 > SEQ ID NO 11 
< 211 > LENGTH : 119 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 
< 400 > SEOUENCE : 11 
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly &J
Gly Pro Ser Val Phe Leu Phe Pro Pro Ala Leu Glu Asp Leu Leu Leu 
25 30 
Gly Ser Glu Ala Asn Val Thr Cys Val Val Val Asp Val Ser His Glu 
& Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 




E? 2 sam mmm mmm Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr Arg 65 70 mmm AE Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly Lys 85 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 105 110 Lys Thr Ile Ser Lys Ala Lys 115 
| AAAAAN INNNEPE Now A
< 210 > SEQ ID NO 12 
< 211 > LENGTH : 120 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide s 
< 400 > SEQUENCE : 12 
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 
& ? & Gly Pro Ser Val Phe Leu Phe Pro Pro Ala Leu Glu Asp Leu Leu Leu 
25 
am J Gly Ser Glu Ala Asn Gly Val Thr Cys Val Val Val Asp Val Ser His 35 40 
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val mms me His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Tyr Asn Ser Thr Tyr sm mm 
sm 
mm Arg Val Val Ser Val Leu Thr Val Leu His Gin Asp Trp Leu Asn Gly 85 & Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile &105 ?Glu Lys Thr Ile Ser Lys Ala Lys 115 120 
AAA 
< 210 > SEQ ID NO 13 
< 211 > LENGTH : 233 
< 212 > TYPE : PRT 
<213 > ORGANISM : Homo sapiens 
< 400 > SEQUENCE : 13 
US 9 , 890 , 216 B2 
AS 44 
- continued 
Val Pro Cys Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro Ser Thr & &?8 &
15 
Pro Pro Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser Leu His Eg 
g
ass ?|1&RE & EE
& 
Arg Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn Leu Thr 
40 




Thr Pro Ser Ser Gly Lys Ser Ala Val Gin Gly Pro Pro Glu Arg Asp 
65 80 
Leu Cys Gly cys Tyr Ser Val Ser Ser Val Leu Pro Gly cys Ala Glu 
95 
Pro Trp Asn His Gly Lys Thr Phe Thr cys Thr Ala Ala Tyr Pro Glu 
Ser Lys Thr Pro Leu Thr Ala Thr Leu Ser Lys Ser Gly Asn Thr Phe 
120 
Arg Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu gam Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser Pro Lys 
145 160 A BE & ER
Asp Val Leu Val Arg Trp Leu Gin Gly Ser Gin Glu Leu Pro Arg Glu 
Lys Tyr Leu Thr Trp Ala Ser Arg Gin Glu Pro Ser Gin Gly Thr Thr 
Thr Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala Glu Asp Trp Lys 
200 
Lys Gly Asp Thr Phe Ser Cys Met Val Gly His Glu Ala Leu Pro Leu 
220 cys Met Val Gly His &
| 
Ala Phe Thr Gln Lys Thr Ile Asp Arg 
225 230 
< 210 > SEQ ID NO 14 
< 211 > LENGTH : 13 
< 212 > TYPE : PRT 
13 > ORGANISM : Homo gapiens v 
< 400 > SEQUENCE : 14 
Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn 
10 
1 
< 210 > SEQ ID NO 15 
< 211 > LENGTH : 14 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic peptide AAAA 1 2 303 2 
< 400 > SEQUENCE : 15 
Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn Gly 
10 
< 210 > SEQ ID No 16 
< 211 > LENGTH : 14 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic polypeptide 303 
< 400 > SEQUENCE : 16 
US 9 , 890 , 216 B2 
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Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 
10 
< 210 > SEQ ID NO 17 
< 211 > LENGTH : 33 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
A 
< 400 > SEQUENCE : 17 
gcgttggaag accttgcgct tggtagcgaa gcg 33 
< 210 > SEQ ID NO 18 
< 211 > LENGTH : 33 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 18 




< 210 > SEQ ID NO 19 
< 211 > LENGTH : 38 
TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 






< 400 > SEQUENCE : 19 
cgttggaaga ccttctggcg ggtagcgaag cgaatctg 38 
? 
< 210 > SEQ ID NO 20 
< 211 > LENGTH : 38 
TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
? 
< 400 > SEQUENCE : 20 




< 210 > SEQ ID NO 21 
< 211 > LENGTH : 33 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
? 
? 
< 400 > SEQUENCE : 21 
ctgtcgggtt gcgcagcgcc gtggaatcat ggc 33 
< 210 > SEQ ID NO 22 
< 211 > LENGTH : 33 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 22 
gccatgattc cacggcgctg cgcaacccga cag 33 
< 210 > SEQ ID NO 23 
< 211 > LENGTH : 38 
US 9 , 890 , 216 B2 
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< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 23 
ggttgcgcag aaccgtgggc gcatggcaaa acattcac 38 
< 210 > SEQ ID NO 24 
< 211 > LENGTH : 38 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 24 
gtgaatgttt tgccatgcgc ccacggttct gcgcaacc 38 
< 210 > SEQ ID NO 25 
< 211 > LENGTH : 37 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer W OWN
< 400 > SEQUENCE : 25 
gcgcagaacc gtggaatgcg ggcaaaacat tcacctg 37 
< 210 > SEQ ID NO 26 
< 211 > LENGTH : 37 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 26 
caggtgaatg ttttgcccgc attccacggt tctgcgc 37 
? 
< 210 > SEQ ID NO 27 
< 211 > LENGTH : 36 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
? 
< 400 > SEQUENCE : 27 
cgaaagatgt tctggtggcg tggctgcagg gaagcc 36 
? .
< 210 > SEQ ID NO 28 
< 211 > LENGTH : 36 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 






< 400 > SEQUENCE : 28 
ggcttccctg cagecacgcc accagaacat ctttcg 36 
< 210 > SEQ ID NO 29 
< 211 > LENGTH : 32 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 29 
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tgcagggaag ccaagcgctg ccccgtgaaa ag 32 
< 210 > SEQ ID NO 30 
< 211 > LENGTH : 32 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 30 
cttttcacgg ggcagcgctt ggcttccctg ca 32 
? 
< 210 > SEQ ID NO 31 
< 211 > LENGTH : 32 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
? MO ? 
? 
< 400 > SEQUENCE : 31 
gatacgttca gctgcgcggt gggccatgag gc 32 
< 210 > SEQ ID NO 32 
< 211 > LENGTH : 32 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
ME?? 
? 
< 400 > SEQUENCE : 32 
gcctcatggc ccaccgcgca gctgaacgta to 32 
< 210 > SEQ ID NO 33 
< 211 > LENGTH : 27 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
M E??
? 
< 400 > SEQUENCE : 33 
atggtgggcc atgcggcact tccgctg 27 
< 210 > SEO ID NO 34 
< 211 > LENGTH : 27 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
NN PPPWO NP
< 400 > SEQUENCE : 34 
cagcggaagt gccgcatggc ccaccat 27 
? 
< 210 > SEO ID NO 35 
< 211 > LENGTH : 37 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 






< 400 > SEQUENCE : 35 
gccatgaggc acttccggcg gcctttactc aaaaaac 37 
< 210 > SEQ ID NO 36 
< 211 > LENGTH : 37 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
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< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 36 
gttttttgag taaaggccgc cggaagtgcc tcatggo 37 
< 210 > SEQ ID NO 37 
< 211 > LENGTH : 40 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 37 
gaggcacttc cgctggccgc gactcaaaaa actattgato 40 
< 210 > SEQ ID NO 38 
< 211 > LENGTH : 40 
< 212 > TYPE : DNA 
13 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
? 
< 400 > SEQUENCE : 38 
gatcaatagt tttttgagtc gcggccagcg gaagtgcctc 40 
< 210 > SEQ ID NO 39 
< 211 > LENGTH : 19 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 39 
cgaggctgat cagcgagct 19 
< 210 > SEQ ID NO 40 
< 211 > LENGTH : 18 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 40 
tgagcggccg ctcgaggc 18 
< 210 > SEO ID NO 41 
< 211 > LENGTH : 36 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
N MOM
< 400 > SEQUENCE : 41 
tttgcccgcc agcctgtcga tggtcttctg ggtgaa 36 
< 210 > SEQ ID NO 42 
< 211 > LENGTH : 62 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
? 
< 400 > SEQUENCE : 42 
cgacaggctg gcgggcaaag goggcggcgg cagccagaga ttctgcaccg gocacttcgg 60 





< 210 > SEQ ID NO 43 
< 211 > LENGTH : 27 
TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 43 
tgatctagaa gctcgctgat cagcctc 27 
< 210 > SEQ ID NO 44 
< 211 > LENGTH : 43 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
MO 
< 400 > SEQUENCE : 44 
gcctttctct ccacaggcgc gcactccgtg cegagcaccc CCC 
< 210 > SEQ ID NO 45 
< 211 > LENGTH : 53 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
ME?? 
? 
< 400 > SEQUENCE : 45 
cgaggctgat cagcgagctt ctagatcagt gatggtgatg atggtgtttg ccc 53 
< 210 > SEQ ID NO 46 
< 211 > LENGTH : 40 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
M E??
? 
< 400 > SEQUENCE : 46 
ggacaatggt caccgtctcc tcagcgagcc cgacgtctcc 40 
< 210 > SEO ID NO 47 
< 211 > LENGTH : 79 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 47 
agatcatttg gctgatcagc gagcttctag atcatttgcc cgccagacga tcaatagttt 
? a
tttgagtaaa ggccagcgg 
< 210 > SEQ ID NO 48 
< 211 > LENGTH : 57 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 48 
gcctcgagcg gccgctcagc cgttgcaggg gtgcaggccg ccgaagtggc cggtgca 57 57 
< 210 > SEQ ID NO 49 
< 211 > LENGTH : 62 
US 9 , 890 , 216 B2 
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< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 49 
cgacaggctg gcgggcaaag gcggcggcgg cagccagaga ttcgtgaccg gocacttcgg 
cg 
< 210 > SEO ID NO 50 
< 211 > LENGTH : 84 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer NNPP 
< 400 > SEQUENCE : 50 
accgtcagtc ttcctcttcc cccccgcgtt ggaagacctt ctgcttggta gcgaagcgaa 60 
tggcgtcaca tgcgtggtgg tgga 
< 210 > SEQ ID NO 51 
< 211 > LENGTH : 57 
< 212 > TYPE : DNA 
13 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
? 
? NNN ? 
< 400 > SEQUENCE : 51 
gcctcgagcg gccgctcagc cgttggcggg gtacaggccg ccgaagtggc cggtcac 57 
< 210 > SEQ ID NO 52 
< 211 > LENGTH : 47 
< 212 > TYPE : DNA 
13 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
A 
A NNN A 
< 400 > SEQUENCE : 52 
cccatcgaga aaaccatctc caaagccagc ggcaacacct tcagacc 47 
< 210 > SEQ ID NO 53 
< 211 > LENGTH : 39 
< 212 > TYPE : DNA 
ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
? 
< 400 > SEQUENCE : 53 
tcagtcttcc tcttcccccc agccctggag gacttgctg 39 
< 210 > SEO ID NO 54 
< 211 > LENGTH : 94 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
223 > OTHER INFORMATION : Synthetic primer ? 
< 400 > SEQUENCE : 54 
tttctctcca caggcgcgca ctccgacaaa actcacacat goccaccgtg cccagcacct i 
gaactcctgg ggggaccgtc agtcttcctc ttcc de a
< 210 > SEQ ID NO 55 
< 211 > LENGTH : 104 
< 212 > TYPE : DNA 
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< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 55 
ggtcttcgtg gctcacgtcc accaccacgc atgtgacctc aggggtccgg gagatcatga 60 
gggtgtcctt gggttttggg gggaagagga agactgacgg tccc 104 
< 210 > SEQ ID NO 56 
< 211 > LENGTH : 101 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 56 
ggtcttcgtg gotcacgtcc accaccacgc acgtcacgtt ggcctcgctg cccagcagca 60 
agtcctccag ggctgggggg aagaggaaga ctgacggtccc 101 
< 210 > SEQ ID NO 57 
< 211 > LENGTH : 104 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 57 
ggtcttogtg gotcacgtcc accaccacgc acgtcacgoc gttggcctcg ctgcccagca 60 
gcaagtcctc cagggctggg gggaagagga agactgacgg tccc 104 
< 210 > SEQ ID NO 58 
< 211 > LENGTH : 99 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
? 
< 400 > SEQUENCE : 58 
gtggacgtga gccacgaaga ccctgaggtc aagttcaact ggtacgtgga cggcgtggag i 




< 210 > SEQ ID NO 59 
< 211 > LENGTH : 102 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
? 
? 
< 400 > SEQUENCE : 59 
ggagaccttg cacttgtact ccttgccatt cagccagtcc tggtgcagga cggtgaggac 60 
gctgaccaca cggtacgtgc tgttgtactg ctcctcccgc gg 102 
< 210 > SEQ ID NO 60 
< 211 > LENGTH : 105 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 60 
gcaaggagta caagtgcaag gtctccaaca aagccctccc agcccccatc gagaaaacca 60 
tctccaaagc cagcggcaac accttcagac ccgaggtgca tctgc 105 
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< 210 > SEQ ID NO 61 
< 211 > LENGTH : 107 
12 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 61 
gcacgtcctt ggggctgaag cccctcgcaa ggcaggtgag agtgaccagc tcgttcaggg 60 
cgagctcctc gctgggaggg ggcagcagat gcacctcggg totgaag 107 
? 
? ? 
< 210 > SEQ ID NO 62 
< 211 > LENGTH : 106 
TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 62 
cttcagcccc aaggacgtgc tcgtgaggtg gctgcagggc toccaggagc tgcccaggga 60 
gaagtacctg acctgggcca gcaggcagga gcccagccaa ggcacc 106 
< 210 > SEQ ID NO 63 
< 211 > LENGTH : 106 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
20 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
A 
< 400 > SEQUENCE : 63 
cctcgtggcc aaccatgcaa gagaaagtgt cgcccttctt ccagtcctcc gcagcgaccc 60 
tcaggatgct ggtgacggcg aaggtggtgg tgccttggct gggctc 106 
< 210 > SEQ ID NO 64 
< 211 > LENGTH : 89 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
23 > OTHER INFORMATION : Synthetic primer ? 
< 400 > SEQUENCE : 64 
cttgcatggt tggccacgag gccctgcccc tggccttcac ccagaagacc atcgacaggc 
accaccatca tcaccactga tctagaagc 
? .
< 210 > SEQ ID NO 65 
< 211 > LENGTH : 46 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 






< 400 > SEQUENCE : 65 
cgaggctgat cagcgagctt ctagatcagt ggtgatgatg gtggtg 46 
< 210 > SEQ ID NO 66 
< 211 > LENGTH : 13 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Homo sapiens 
< 400 > SEQUENCE : 66 
Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn 
10 
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< 210 > SEQ ID NO 67 
< 211 > LENGTH : 16 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic pepetide 
< 400 > SEQUENCE : 67 
Gin Arg Phe Val Thr Gly His Phe Gly Gly Leu Tyr Pro Ala Asn Gly 
10 15 
< 210 > SEQ ID NO 68 
< 211 > LENGTH : 16 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic pepetide 
MO 
< 400 > SEQUENCE : 68 
Gin Arg Phe cys Thr Gly His Phe Gly Gly Leu His Pro Cys Asn Gly 
10 15 
< 210 > SEQ ID NO 69 
< 211 > LENGTH : 16 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 69 
tgagcggccg ctcgag 16 
< 210 > SEQ ID NO 70 
< 211 > LENGTH : 24 
< 212 > TYPE : DNA 
ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 70 
acactggaca cctttgagca cago 24 
< 210 > SEQ ID NO 71 
< 211 > LENGTH : 47 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 71 
cgctgtgctc aaaggtgtcc agtgtcaagc tgctccccca aaggctg 47 
< 210 > SEQ ID NO 72 
< 211 > LENGTH : 47 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
N PEP
< 400 > SEQUENCE : 72 
cgctgtgctc aaaggtgtcc agtgtacacc tgcagctccc ccaaagg 47 
< 210 > SEQ ID NO 73 
< 211 > LENGTH : 40 
< 212 > TYPE : DNA 
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< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 1 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 73 
gtggtgatgg tgatgatgccccattggtga agagctgccc 40 
< 210 > SEQ ID NO 74 
< 211 > LENGTH : 42 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial sequence 
< 220 > FEATURE : 
< 223 > OTHER INFORMATION : Synthetic primer 
AAAA 1 130 1 2
2 
< 400 > SEQUENCE : 74 
gtggtgatgg tgatgatggg gagcttggac agtgatggtc ac 42 .
< 210 > SEQ ID NO 75 
< 211 > LENGTH : 26 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : | 
< 223 > OTHER INFORMATION : Synthetic primer 
< 400 > SEQUENCE : 75 
cgccttatcc ggtaactatc gtcttg 26 
< 210 > SEQ ID No 76 
< 211 > LENGTH : 26 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Artificial Sequence 
< 220 > FEATURE : 




< 400 > SEQUENCE : 76 
gactcaagac gatagttacc ggataa 26 
< 210 > SEQ ID No 77 
< 211 > LENGTH : 353 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Homo sapiens 
< 400 > SEQUENCE : 77 





Gin Pro Asp Gly Asn Val Val Ile Ala Cys Leu Val Gin Gly Phe Phe 
Pro Gin Glu Pro Leu Ser Val Thr Trp Ser Glu Ser Gly Gin Gly Val 
40 45 35 
Thr Ala Arg Asn Phe Pro Pro Ser Gin Asp Ala Ser Gly Asp Leu Tyr 
55 
mm me mm 8mm . am mmm Thr Thr Ser Ser Gin Leu Thr Leu Pro Ala Thr Gin Cys Leu Ala Gly &Lys Ser Val Thr Cys His Val Lys His Tyr Thr Asn Pro Ser Gin Asp EA ?8 ? & Val Thr Val Pro Cys Pro Val Pro Ser Thr Pro Pro Thr Pro Ser Pro 
? Ser Thr Pro Pro Thr Pro Ser Pro Ser Cys Cys His Pro Arg Leu Ser 
115 120 125 
Leu His Arg Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn 
135 
3
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Leu Thr Cys Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr Phe 
145 150 155 160 





E Arg Asp Leu cys Gly Cys Tyr Ser Val Ser Ser Val Leu Pro Gly Cys 
190 
83BE 1 Ala Glu Pro Trp Asn His Gly Lys Thr Phe Thr Cys Thr Ala Ala Tyr 200 205 
Pro Glu Ser Lys Thr Pro Leu Thr Ala Thr Leu Ser Lys Ser Gly Asn 
220 
Thr Phe Arg Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu 
225 230 235 240 mmm Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser 255 
3 mmm mmmm ? & Sag3?Pro Lys Asp Val Leu Val Arg Trp Leu Gin Gly Ser Gin Glu Leu Pro 270 Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gin Glu Pro Ser Gin Gly 280 285 mmm Thr Thr Thr Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala Glu Asp 300 Trp Lys Lys Gly Asp Thr Phe Ser Cys Met Val Gly His Glu Ala Leu 305 310 315 320 3 & Pro Leu Ala Phe Thr Gin Lys Thr Ile Asp Arg Leu Ala Gly Lys Pro335 Thr His Val Asn Val Ser Val Val Met Ala Glu Val Asp Gly Thr Cys 350 ? RTyr 
< 210 > SEQ ID No 78 
< 211 > LENGTH : 340 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Homo sapiens 
< 400 > SEQUENCE : 78 mmm Ala Ser Pro Thr Ser Pro Lys Val Phe Pro Leu Ser Leu Asp Ser Thr Pro Gln Asp Gly Asn Val Val Val Ala Cys Leu Val Gln Gly Phe Phe 25 &3 & Pro Gin Glu Pro Leu Ser Val Thr Trp Ser Glu Ser Gly Gin Asn Val 33 Jg 8 gn &JE A & E ? E SE ? Thr Ala Arg Asn Phe Pro Pro Ser Gin Asp Ala Ser Gly Asp Leu Tyr Thr Thr Ser Ser Gin Leu Thr Leu Pro Ala Thr Gin Cys Pro Asp Gly 
7 0 






5 smmam Val Thr Val Pro Cys Pro Val Pro Pro Pro Pro Pro Cys Cys His Pro 105 Arg Leu Ser Leu His Arg Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn Leu Thr Cys Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly ?gE
Ala Thr Phe Thr Trp Thr Pro Ser Ser Gly Lys Ser Ala Val Gin Gly 
150 ?? 
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3 ? E 
? 
Pro Gly Cys Ala Gin Pro Trp Asn His Gly Glu Thr Phe Thr Cys Thr 
185 190 







12 ?3 & 
& Ser Gly Asn Thr Phe Arg Pro Glu Val His Leu Leu Pro Pro Pro Ser 
215 220 mmmm ? Glu Glu Leu Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arq 230 240 Gly Phe Ser Pro Lys Asp Val Leu Val Arg Trp Leu Gin Gly Ser Gin 255 
Glu Leu Pro Arq Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gln Glu Pro 
265 270 
Ser Gin Gly Thr Thr Thr Phe Ala Val Thr Ser Ile Leu Ara Val Ala 
275 280 
Ala Glu Asp Trp Lys Lys Gly Asp Thr Phe Ser Cys Met Val Gly His 
295 300 
Glu Ala Leu Pro Leu Ala Phe Thr Gin Lys Thr Ile Asp Arg Met Ala 
310 320 
| | | 1 | . 
Gly Lys Pro Thr His Val Asn Val Ser Val Val Met Ala Glu Val Asp 
325 335 
Gly Thr Cys Tyr 
340 
< 210 > SEQ ID No 79 
< 211 > LENGTH : 344 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Mus musculus 
< 400 > SEQUENCE : 
Glu Ser Ala Ara Asn Pro Thr Ile Tyr Pro Leu Thr Leu Pro Pro Ala ?So . 
Leu Ser Ser Asp Pro Val Ile Ile Gly cys Leu Ile His Asp Tyr Phe 
20 30 | 
Pro Ser Gly Thr Met Asn Val Thr Trp Gly Lys Ser Gly Lys Asp Ile 
45 40 
& A
& EEJThr Thr Val Asn Phe Pro Pro Ala Leu Ala Ser Gly Gly Arg Tyr Thr 
Met Ser Asn Gin Leu Thr Leu Pro Ala Val Glu Cys Pro Glu Gly Glu 
75 mmmmm Ser Val Lys Cys Ser Val Gin His Asp Ser Asn Pro Val Gin Glu Leu 85 & & & Asp Val Asn Cys Ser Gly Pro Thr Pro Pro Pro Pro Ile Thr Ile Pro 100 110 R & Ser Cys Gin Pro Ser Leu Ser Leu Gin Arg Pro Ala Leu Glu Asp Leu 120 125 mmm mmm Leu Leu Gly Ser Asp Ala Ser Ile Thr Cys Thr Leu Asn Gly Leu Arg E?Asn Pro Glu Gly Ala Val Phe Thr Trp Glu Pro Ser Thr Gly Lys Asp 155 Ala Val Gin Lys Lys Ala Val Gin Asn Ser Cys Gly Cys Tyr Ser Val 165 Ser Ser Val Leu Pro Gly Cys Ala Glu Arg Trp Asn Ser Gly Ala Ser 180 190 
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Phe Lye Le Phe Lys Cys Thr Val Thr His Pro Glu Ser Gly Thr Leu Thr Gly Thr 200 205 








. ? ? 
Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu Leu Leu Ser Leu Thr 
225 240 mmm Cys Leu Val Arg Ala Phe Asn Pro Lys Glu Val Leu Val Arg Trp Leu 245 250 255 His Gly Asn Glu Glu Leu Ser Pro Glu Ser Tyr Leu Val Phe Glu Pro 270 
Leu Lys Glu Pro Gly Glu Gly Ala Thr Thr Tyr Leu Val Thr Ser Val 
275 280 285 
Leu Arg Val Ser Ala Glu Thr Trp Lys Gin Gly Asp Gin Tyr Ser Cys 
295 
&
JES E3gan ? Met Val Gly His Glu Ala Leu Pro Met Asn Phe Thr ln Lys Thr Ile 305 320 | Asp Arg Leu Ser Gly Lys Pro Thr Asn Val Ser Val Ser Val Ile Met 
225 330 335 
Ser Glu Gly Asp Gly Ile Cys Tyr 
340 
< 210 > SEQ ID NO 80 
< 211 > LENGTH : 299 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Oryctolagus cuniculus 
< 400 > SEQUENCE : 80 
Gin Ser Gly Thr Ser Gly Pro Tyr Thr Ala Cys Ser Glu Leu Ile Leu 3&.
Pro Val Thr Gin Cys Leu Gly Gin Lys Ser Ala Ala cys His Val Glu 
20 25 30 
Tyr Asn Ser Val Ile Asn Glu Ser Leu Pro Val Pro Phe Pro Asp Cys 
40 
&
Cys Pro Ala Asn Ser Cys Cys Thr Cys Pro Ser Ser Ser Ser Arg Asn E
55 
& & Leu Ile Ser Gly Cys Gln Pro Ser Leu Ser Leu Gin Arg Pro Asp Leu 
65 75 5mm a? mmmm mmmmm msm mm8mmGly Asp Leu Leu Leu Gly Arg Asp Ala Ser Leu Thr Cys Thr Leu Ser mmmmm &?? ?Gly Leu Lys Asn Pro Glu Asp Ala Val Phe Thr Trp Glu Pro Thr Asn 100 105 110 Gly Asn Glu Pro Val Gin Gin Arg Ala Gin Arg Asp Leu Ser Gly Cys 120 Tyr Ser Val Ser Ser Val Leu Pro Ser Ser Ala Glu Thr Trp Lys Ala 135 | | Arg Thr Glu Phe Thr Cys Thr Val Thr His Pro Glu Ile Asp Ser Gly 145 150 155 160 Ser Leu Thr Ala Thr Ile Ser Arg Gly Val Val Thr Pro Pro Gin Val 165 
His Leu Leu Pro Pro Pro Ser Glu Glu Leu Ala Leu Asn Glu Gin Val 
180 185 190 mmm Thr Leu Thr cys Leu Val Arg Gly Phe Ser Pro Lys Asp Val Leu Val 200 
Ser Trp Arg His Gin Gly Gin Glu Val Pro Glu Asp Ser Phe Leu Val 




Trp Lys Ser Met Pro Glu Ser Ser Gin Asp Lys Ala Thr Tyr Ala Ile 
230 240 
Thr Ser Leu Leu Arq Val Pro Ala Glu Asp Trp Asn Gln Gly Asp Thr 
245 250 255 
Tyr Ser Cys Met Val Gly His Glu Gly Leu Ala Glu His Phe Thr Gln 
260 265 




Val Val Val Ala Asp Val Glu Ala Val Cys Tyr 
290 295 
< 210 > SEQ ID NO 81 
< 211 > LENGTH : 353 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Gorilla gorilla 
< 400 > SEQUENCE : 81 
Ala Ser Pro Thr Ser Pro Lys Val Phe Pro Leu Ser Leu Cys Ser Thr 
9 15 







Pro Gin Glu Pro Leu Ser Val Thr Trp Ser Glu Ser Gly Gin Gly Val 
40 
Thr Ala Arg Asn Phe Pro Pro Ser Gin Asp Ala Ser Gly Asp Leu Tyr 
Thr Thr Ser Ser Gin Leu Thr Leu Pro Ala Thr Gin Cys Pro Asp Gly 
65 7 0 
Lys Ser Val Thr Cys His Val Asn His Tyr Thr Asn Pro Ser Gin Asp 
95 
Val Thr Val Pro Cys Ara Val Pro Ser Thr Pro Pro Thr Pro Ser Pro 
105 
Ser Thr Pro Pro Thr Pro Ser Pro Pro Cys Cys His Pro Arg Leu Ser 
120 
Leu His Arq Pro Ala Leu Glu Asp Leu Leu Leu Gly Ser Glu Ala Asn 
F
am Leu Thr Cys Thr Leu Thr Gly Leu Arg Asp Ala Ser Gly Val Thr Phe 145 150 8 ? & 2 ?3? EER 3& E A R 3 R &?EEdE mmmmmm g am Thr Trp Thr Pro Ser Ser Gly Lys Ser Ala Val Glu Gly Pro Pro Glu 175 mmmm Arg Asp Leu Cys Gly Cys Tyr Ser Val Ser Ser Val Leu Pro Gly Cys 185 Ala Glu Pro Trp Asn His Gly Lys Thr Phe Thr Cys Thr Ala Ala Tyr 200 Pro Glu Ser Lys Thr Pro Leu Thr Ala Thr Leu Ser Lys Ser Gly Asn Met Phe Arq Pro Glu Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu 225 230 Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Ala Arg Gly Phe Ser 255 Pro Lys Asp Val Leu Val Arg Trp Leu Gin Gly Ser Gin Glu Leu Pro 265 Arg Glu Lys Tyr Leu Thr Trp Ala Ser Arg Gin Glu Pro Ser Gin Gly 280 
US 9 , 890 , 216 B2 
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- continued 
? Thr Thr Thr Phe Ala Val Thr Ser Ile Leu Arg Val Ala Ala Glu Asp 
290 295 300 
2 ? ? ? Gly His Glu Ala Leu 
315 320 305 310 ER & Pro Leu Ala Phe Thr Gin Lys Thr Ile Asp Arg Leu Ala Gly Lys Pro 325 335 
Thr His Val Asn Val Ser Val Val Met Ala Glu Val Asp Gly Thr Cys 
340 345 350 ? Val Asp Gay Thr cys 
Tyr 
< 210 > SEQ ID NO 82 
< 211 > LENGTH : 337 
< 212 > TYPE : PRT 
213 > ORGANISM : Sus scrofa vv  
< 400 > SEQUENCE : 82 
Ser Glu Thr Ser Pro Lys Ile Phe Pro Leu Thr Leu Gly Ser Ser Glu 
Pro Ala Gly Tyr Val Val Ile Ala Cys Leu Val Arg Asp Phe Phe Pro 
20 30 .
Ser Glu Pro Leu Thr Val Thr Trp Ser Pro Ser Arg Glu Gly Val Ile 
35 40 1 







Ser Gin Leu Thr Leu Pro Val Glu Gin Cys Pro Ala Asp Gin Ile Leu 
75 
Lys Cys Gin Val Gln His Leu Ser Lys Ser Ser Gin Ser Val Asn Val 






? Gln Pro Pro Ala Leu Ala Asp Leu Leu Leu Gly Ser Asn Ala Ser Leu 
115 120 
Thr Cys Thr Leu Ser Gly Leu Lys Lys Ser Glu Gly Val Ser Phe Thr 
130 
Trp Gin Pro Ser Gly Gly Lys Asp Ala Val Gin Ala Ser Pro Thr Arg 
155 
&
mmmm 8 mama 
mmmmmmm mm 
Asp Ser Cys Gly Cys Tyr Ser Val Ser Ser Ile Leu Pro Gly cys Ala 
Asp Pro Trp Asn Lys Gly Glu Thr Phe Ser Cys Thr Ala Ala His Ser 
180 190 
&
Glu Leu Lys Ser Ala Leu Thr Ala Thr Ile Thr Lys Pro Lys Val Asn 
195 200 
Thr Phe Arg Pro Gin Val His Leu Leu Pro Pro Pro Ser Glu Glu Leu 
210 
Ala Leu Asn Glu Leu Val Thr Leu Thr Cys Leu Val Arg Gly Phe Ser 
235 
Pro Lys Asp Val Leu Val Arg Trp Leu Gin Gly Gly Gin Glu Leu Pro 
& Re
& ? 
Arg Asp Lys Tyr Leu Val Trp Glu Ser Leu Pro Glu Pro Gly Gin Ala 
260 
Ile Pro Thr Tyr Ala Val Thr Ser Val Leu Arg Val Asp Ala Glu Asp 
275 280 8 
Trp Lys Gin Gly Asp Thr Phe Ser Cys Met Val Gly His Glu Ala Leu 
290 
US 9 , 890 , 216 B2 
75 
- continued 
Pro Leu Ala Phe Thr Gin Lys Thr Ile Asp Arg Leu Ala Gly Lys Pro 
305 310 315 320 
Thr His Val Asn Val Ser Val Val Met Ala Glu Ala Glu Gly Ile Cys 
325 330 335 
Tyr 
10 
What is claimed is : 12 . The antibody of claim 8 , wherein the antibody binds 
1 . A recombinant polypeptide comprising a single immu - to a cancer cell antigen . 
noglobulin Fc domain , the Fc domain consists of at least 13 . The antibody of claim 11 , wherein the antibody binds 
85 % sequence identity to the sequence of SEQ ID NO : 8 , to an EGFR or VEGFR . 
and wherein the immunoglobulin Fc domain consists of ( a ) 15 14 . The antibody of claim 13 , wherein the antibody binds 
a single chimeric CH2 domain having an al loop corre - to HER2 . 
sponding to amino acids 245 - 257 of a human IgA Fc , 15 . The antibody of claim 8 , wherein the antibody is 
according to the Kabat numbering scheme , and ( b ) a single coupled to a therapeutic , a reporter , or a targeting moiety . 
CH3 domain . 16 . The antibody of claim 15 , wherein the therapeutic is 2 . The polypeptide of claim 1 , further comprising an 20 ani ! ! , Turther comprising an 20 a nucleotide , a peptide , a small molecule , a therapeutic immunoglobulin variable domain . radionuclide , a chemotherapeutic , a tumor suppressor , an 3 . The polypeptide of claim 1 , wherein the single chimeric apoptosis inducer , an enzyme , a second antibody , an siRNA , CH2 domain is a CH2y domain comprising said al loop , a hormone , a prodrug , or an immunostimulant . and / or the CH3 domain is a CH3a domain . 
4 . The polypeptide of claim 1 , wherein the al loop 25 17 . The antibody of claim 8 , wherein the antibody com 
domain comprises the sequence PALEDLLLGSEAN ( SEO prises one or more of the following : 
ID NO : 14 ) . ( a ) decreased affinity for FcyRIIb relative to a wild type 
5 . The polypeptide of claim 1 , wherein the immunoglobu IgG antibody ; 
lin Fc domain comprises the sequence PALEDLLLGSE - ( b ) increased affinity for FcyRIIa relative to a wild type 
ANG ( SEQ ID NO : 15 ) . IgA antibody ; 
6 . The polypeptide of claim 1 , further comprising a ( c ) increased affinity for FcyRI relative to a wild type IgA 
FcRn - binding peptide at the C - terminus . antibody ; and 
7 . The polypeptide of claim 6 , wherein the FcRn - binding ( d ) increased affinity for FcaRI relative to a wild type IgG 
peptide is the linear peptide of SEQ ID NO : 67 or the cyclic antibody . 
peptide of SEQ ID NO : 68 . 35 18 . A composition comprising the recombinant antibody 
8 . A recombinant antibody comprising the polypeptide of claim 8 and a buffer . diluent or excipient . 
sequence in accordance with claim 1 . 19 . The polypeptide of claim 1 , wherein the immuno 9 . The antibody of claim 8 , wherein the antibody is a globulin Fc domain consisting a sequence at least 90 % human or humanized antibody . identical to SEQ ID NO : 8 . 10 . The antibody of claim 8 , wherein the antibody is 40 
aglycosylated . 20 . The antibody of claim 8 , wherein the antibody is a 
11 . The antibody of claim 8 , wherein the antibody binds dy of claims wherein the antibody hinda bis bispecific antibody . 
to a cell surface antigen . 
30 
* * * * 
